<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10094987</article-id><article-id pub-id-type="pmcid-ver">PMC10094987.1</article-id><article-id pub-id-type="pmcaid">10094987</article-id><article-id pub-id-type="pmcaiid">10094987</article-id><article-id pub-id-type="pmid">37047397</article-id><article-id pub-id-type="doi">10.3390/ijms24076424</article-id><article-id pub-id-type="publisher-id">ijms-24-06424</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Response Variability to Drug Testing in Two Models of Chemically Induced Colitis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3754-4768</contrib-id><name name-style="western"><surname>Suau</surname><given-names initials="R">Roger</given-names></name><xref rid="af1-ijms-24-06424" ref-type="aff">1</xref><xref rid="af2-ijms-24-06424" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garcia</surname><given-names initials="A">Anna</given-names></name><xref rid="af1-ijms-24-06424" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bernal</surname><given-names initials="C">Carla</given-names></name><xref rid="af3-ijms-24-06424" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Llaves</surname><given-names initials="M">Mariona</given-names></name><xref rid="af1-ijms-24-06424" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schiering</surname><given-names initials="K">Katharina</given-names></name><xref rid="af4-ijms-24-06424" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jou-Oll&#233;</surname><given-names initials="E">Eva</given-names></name><xref rid="af1-ijms-24-06424" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pertegaz</surname><given-names initials="A">Alex</given-names></name><xref rid="af1-ijms-24-06424" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garcia-Jaraquemada</surname><given-names initials="A">Arce</given-names></name><xref rid="af1-ijms-24-06424" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bartol&#237;</surname><given-names initials="R">Ramon</given-names></name><xref rid="af2-ijms-24-06424" ref-type="aff">2</xref><xref rid="af5-ijms-24-06424" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lor&#233;n</surname><given-names initials="V">Violeta</given-names></name><xref rid="af1-ijms-24-06424" ref-type="aff">1</xref><xref rid="af2-ijms-24-06424" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vergara</surname><given-names initials="P">Patri</given-names></name><xref rid="af2-ijms-24-06424" ref-type="aff">2</xref><xref rid="af6-ijms-24-06424" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9051-2581</contrib-id><name name-style="western"><surname>Ma&#241;osa</surname><given-names initials="M">M&#237;riam</given-names></name><xref rid="af1-ijms-24-06424" ref-type="aff">1</xref><xref rid="af2-ijms-24-06424" ref-type="aff">2</xref><xref rid="af7-ijms-24-06424" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2315-7196</contrib-id><name name-style="western"><surname>Dom&#232;nech</surname><given-names initials="E">Eugeni</given-names></name><xref rid="af1-ijms-24-06424" ref-type="aff">1</xref><xref rid="af2-ijms-24-06424" ref-type="aff">2</xref><xref rid="af7-ijms-24-06424" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Many&#233;</surname><given-names initials="J">Josep</given-names></name><xref rid="af1-ijms-24-06424" ref-type="aff">1</xref><xref rid="af2-ijms-24-06424" ref-type="aff">2</xref><xref rid="c1-ijms-24-06424" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Serena</surname><given-names initials="C">Carolina</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-24-06424"><label>1</label>IBD Research Group, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain; <email>rsuau@igtp.cat</email> (R.S.); </aff><aff id="af2-ijms-24-06424"><label>2</label>Centro de Investigaci&#243;n Biom&#233;dica en Red Enfermedades Hep&#225;ticas y Digestivas (CIBEREHD), 28029 Madrid, Spain</aff><aff id="af3-ijms-24-06424"><label>3</label>Laboratory of Genetic Metabolic Diseases, Faculty of Biosciences, National University of San Marcos, Lima 15088, Peru</aff><aff id="af4-ijms-24-06424"><label>4</label>Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany</aff><aff id="af5-ijms-24-06424"><label>5</label>Hepatology Unit IGTP, 08916 Badalona, Spain</aff><aff id="af6-ijms-24-06424"><label>6</label>Department of Physiology, Faculty of Veterinary, Autonomous University of Barcelona, 08193 Bellaterra, Spain</aff><aff id="af7-ijms-24-06424"><label>7</label>Gastroenterology Department, Germans Trias i Pujol University Hospital, 08916 Badalona, Spain</aff><author-notes><corresp id="c1-ijms-24-06424"><label>*</label>Correspondence: <email>jmanye@igtp.cat</email>; Tel.: +34-680-72-24-08</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2023</year></pub-date><volume>24</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">433371</issue-id><elocation-id>6424</elocation-id><history><date date-type="received"><day>06</day><month>3</month><year>2023</year></date><date date-type="rev-recd"><day>23</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>13</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-15 23:25:14.293"><day>15</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-24-06424.pdf"/><abstract><p>The lack of knowledge regarding the pathogenesis of IBD is a challenge for the development of more effective and safer therapies. Although in vivo preclinical approaches are critical for drug testing, none of the existing models accurately reproduce human IBD. Factors that influence the intra-individual response to drugs have barely been described. With this in mind, our aim was to compare the anti-inflammatory efficacy of a new molecule (MTADV) to that of corticosteroids in TNBS and DSS-induced colitis mice of both sexes in order to clarify further the response mechanism involved and the variability between sexes. The drugs were administered preventively and therapeutically, and real-time bioluminescence was performed for the in vivo time-course colitis monitoring. Morphometric data were also collected, and colonic cytokines and acute plasma phase proteins were analyzed by qRT-PCR and ELISA, respectively&#8212;bioluminescence images correlated with inflammatory markers. In the TNBS model, dexamethasone worked better in females, while MTADV improved inflammation in males. In DSS-colitis, both therapies worked similarly. Based on the molecular profiles, interaction networks were constructed to pinpoint the drivers of therapeutic response that were highly dependent on the sex. In conclusion, our results suggest the importance of considering sex in IBD preclinical drug screening.</p></abstract><kwd-group><kwd>inflammatory bowel disease</kwd><kwd>Crohn&#8217;s disease</kwd><kwd>ulcerative colitis</kwd><kwd>TNBS-induced colitis</kwd><kwd>DSS-induced colitis</kwd><kwd>bioluminescence</kwd><kwd>sex</kwd><kwd>inflammation</kwd></kwd-group><funding-group><award-group><funding-source>Spherium Biotech (Barcelona, Spain)</funding-source></award-group><award-group><funding-source>CIBEREHD (Madrid, Spain)</funding-source></award-group><award-group><funding-source>Instituto de Salud Carlos III (ISCIII, Government of Spain)</funding-source></award-group><funding-statement>This study is part of a much larger therapeutic screening study funded by Spherium Biotech (Barcelona, Spain). In addition, some molecular assays have been financed through CIBEREHD (Madrid, Spain) and the PI18/00892 project of the Instituto de Salud Carlos III (ISCIII, Government of Spain).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-24-06424"><title>1. Introduction</title><p>Crohn&#8217;s disease (CD) and ulcerative colitis (UC) are the two most common inflammatory bowel diseases (IBD). Both are chronic inflammatory conditions of the gastrointestinal tract and, similar to many immune-mediated diseases, are characterized by a relapsing-remitting pattern with long-lasting cumulative damage in the involved intestine [<xref rid="B1-ijms-24-06424" ref-type="bibr">1</xref>,<xref rid="B2-ijms-24-06424" ref-type="bibr">2</xref>]. Their etiology is, at present, poorly understood and relies not only on genetic but also on environmental factors [<xref rid="B1-ijms-24-06424" ref-type="bibr">1</xref>,<xref rid="B3-ijms-24-06424" ref-type="bibr">3</xref>]. Briefly, unknown environmental factors cause a change in the balance of the gut microbiota that becomes dysbiotic [<xref rid="B3-ijms-24-06424" ref-type="bibr">3</xref>,<xref rid="B4-ijms-24-06424" ref-type="bibr">4</xref>]. This causes a reaction of the immune system that configures the intestinal barrier for the control of these dysbiotic changes. However, IBD-related genetic mutations induce immune system deficiencies that trigger an aberrant response toward the microbiota, which simultaneously damages the host&#8217;s gut [<xref rid="B4-ijms-24-06424" ref-type="bibr">4</xref>,<xref rid="B5-ijms-24-06424" ref-type="bibr">5</xref>]. The complexity of IBD and limited knowledge about its pathogenesis hamper the development of new therapies that are more effective and precise in the selection of specific targets [<xref rid="B6-ijms-24-06424" ref-type="bibr">6</xref>]. Suitable genetic [<xref rid="B7-ijms-24-06424" ref-type="bibr">7</xref>], cell transfer [<xref rid="B8-ijms-24-06424" ref-type="bibr">8</xref>], and chemically induced colitis [<xref rid="B9-ijms-24-06424" ref-type="bibr">9</xref>,<xref rid="B10-ijms-24-06424" ref-type="bibr">10</xref>] in vivo models have been developed and widely used to discern the molecular mechanisms at the onset and during IBD [<xref rid="B10-ijms-24-06424" ref-type="bibr">10</xref>,<xref rid="B11-ijms-24-06424" ref-type="bibr">11</xref>]. However, differences between models and their inability to fully reproduce the pathology as in humans are a barrier to effective drug screening [<xref rid="B9-ijms-24-06424" ref-type="bibr">9</xref>].</p><p>Among the chemically-induced colitis models, the two main and most widely used in drug testing are the TNBS and DSS experimental models. A single intracolonic administration of the ethanol-dissolved TNBS hapten can elicit significant immunologic responses by rendering colonic proteins immunogenic to the host&#8217;s immune system, leading to the development of an excessive Th-1 cell-mediated immune-inflammatory response [<xref rid="B12-ijms-24-06424" ref-type="bibr">12</xref>]. TNBS-induced inflammation generates transmural colonic lesions [<xref rid="B13-ijms-24-06424" ref-type="bibr">13</xref>] that share the hallmarks of human CD [<xref rid="B14-ijms-24-06424" ref-type="bibr">14</xref>]. Severe colitis after TNBS enema is followed by body weight loss, diarrhea, and increased myeloperoxidase (MPO) activity in wild-type mice [<xref rid="B10-ijms-24-06424" ref-type="bibr">10</xref>,<xref rid="B15-ijms-24-06424" ref-type="bibr">15</xref>,<xref rid="B16-ijms-24-06424" ref-type="bibr">16</xref>]. On the other hand, DSS acute colitis is usually induced by continuous administration of 2&#8211;7% DSS in drinking water for a short period. DSS administration provokes erosive lesions in the intestinal mucosa with mucin depletion, epithelial degeneration, and necrosis, leading to the disappearance of epithelial cells [<xref rid="B10-ijms-24-06424" ref-type="bibr">10</xref>,<xref rid="B11-ijms-24-06424" ref-type="bibr">11</xref>,<xref rid="B17-ijms-24-06424" ref-type="bibr">17</xref>]. As with TNBS colitis, the clinical manifestations of DSS acute colitis may also include weight loss and diarrhea but more often consist of occult blood in stool, piloerection, and anemia [<xref rid="B10-ijms-24-06424" ref-type="bibr">10</xref>,<xref rid="B17-ijms-24-06424" ref-type="bibr">17</xref>]. All this leads to epithelial barrier weakening and, therefore, lamina propria transepithelial neutrophilic infiltration, cryptitis, and crypt abscesses [<xref rid="B10-ijms-24-06424" ref-type="bibr">10</xref>]. These changes coexist with the loss of components of the tight-junctions such as the zonula occludens complex (ZO-1) [<xref rid="B18-ijms-24-06424" ref-type="bibr">18</xref>,<xref rid="B19-ijms-24-06424" ref-type="bibr">19</xref>] and a significantly increased production of inflammatory cytokines (TNF-&#945;, IL-1&#946;, IFN-&#947;, IL-6, and IL-12) in the colon, as well as anti-inflammatory IL-10 [<xref rid="B11-ijms-24-06424" ref-type="bibr">11</xref>,<xref rid="B19-ijms-24-06424" ref-type="bibr">19</xref>,<xref rid="B20-ijms-24-06424" ref-type="bibr">20</xref>,<xref rid="B21-ijms-24-06424" ref-type="bibr">21</xref>]. However, the exact mechanisms mediating pathogenesis in both TNBS and DSS models remain elusive. Furthermore, in these IBD models, there are some components, such as sex, which can vary the severity of colitis, even increasing the intra-individual variability of colitis development. In fact, estrogens seem to modulate colitis severity in these models [<xref rid="B22-ijms-24-06424" ref-type="bibr">22</xref>,<xref rid="B23-ijms-24-06424" ref-type="bibr">23</xref>], and even cytokine expression, such as IL-6, is dependent on the sex of the animal [<xref rid="B24-ijms-24-06424" ref-type="bibr">24</xref>]. For instance, DSS colitis was more severe in male mice, and this was estradiol-dependent [<xref rid="B23-ijms-24-06424" ref-type="bibr">23</xref>]. There are studies that have found sex-specific responses to drugs in chemically-induced colitis [<xref rid="B25-ijms-24-06424" ref-type="bibr">25</xref>,<xref rid="B26-ijms-24-06424" ref-type="bibr">26</xref>]. For example, resveratrol, which interacts with estrogen receptors, showed response discrepancies between both sexes in DSS models [<xref rid="B25-ijms-24-06424" ref-type="bibr">25</xref>]. In addition, sex-dependent immune features have been found to be unique for each sex in these models [<xref rid="B27-ijms-24-06424" ref-type="bibr">27</xref>,<xref rid="B28-ijms-24-06424" ref-type="bibr">28</xref>]. Nonetheless, 64% of the preclinical studies with chemically induced colitis models developed so far used only male animals, 21% used females, and only 4% used both sexes. However, IBD incidence in women is somewhat greater than in men [<xref rid="B29-ijms-24-06424" ref-type="bibr">29</xref>].</p><p>All of this makes drug screening difficult and open to reconsideration. For these reasons, it is necessary to gain knowledge regarding the effect sex has on these chemically-induced models in order to improve the experimental designs for drug screening. For this reason, refined experiments, including the assessment of the inflammatory course based on reactive oxygen species (ROS) detection, should be included in experimental designs. Oxidative stress is defined as an imbalance between oxidants and antioxidants, leading to a disruption of redox signaling and inducing molecular damage [<xref rid="B30-ijms-24-06424" ref-type="bibr">30</xref>]. Increased levels of ROS are a hallmark of inflammation and are also elevated in IBD and murine colitis [<xref rid="B31-ijms-24-06424" ref-type="bibr">31</xref>,<xref rid="B32-ijms-24-06424" ref-type="bibr">32</xref>,<xref rid="B33-ijms-24-06424" ref-type="bibr">33</xref>,<xref rid="B34-ijms-24-06424" ref-type="bibr">34</xref>]. The main producers of ROS in IBD are activated neutrophils and macrophages. During inflammatory flare-ups, these cells exhibit massive intestinal mucosa infiltration and release large amounts of these species [<xref rid="B35-ijms-24-06424" ref-type="bibr">35</xref>]. The analog luminol probe L-012 is able to react with ROS and produce a chemiluminescent signal that can be quantified by bioimaging and has been proven to correlate with intestinal inflammation in murine colitis [<xref rid="B32-ijms-24-06424" ref-type="bibr">32</xref>]. This system allows for assessing the inflammatory course of murine colitis in order to reduce the number of animals used and to correct for the variability in the response.</p><p>Thus, we aimed to study drug screening variability depending on the model and the mouse sex in two experimental trials, one preventive and the other therapeutic, also considering the inflammatory course based on ROS detection by bioimaging systems.</p></sec><sec sec-type="results" id="sec2-ijms-24-06424"><title>2. Results</title><sec id="sec2dot1-ijms-24-06424"><title>2.1. Bioluminescence Natural Time-Course in TNBS or DSS Colitis</title><p>The bioluminescent images from the TNBS-induced inflammatory course showed a representative profile of ROS production with two inflammatory outbreaks. The first inflammatory outbreak (early) showed high-intensity signals at 48&#8211;72 h post-TNBS induction (<xref rid="ijms-24-06424-f001" ref-type="fig">Figure 1</xref>A,B). A second inflammatory outbreak (late) was observed from day five to seven. Although there was slight immunosuppression immediately after TNBS-colitis induction, immunosuppression was much more marked after DSS withdrawal (<xref rid="ijms-24-06424-f002" ref-type="fig">Figure 2</xref>A,B). It was not until two days after DSS (day seven) that an inflammatory flare was detected by ROS-induced bioluminescent signal increase. From this point on, bioluminescence gradually decreased as the course of DSS-colitis progressed.</p></sec><sec id="sec2dot2-ijms-24-06424"><title>2.2. Bioluminescence Intensity Correlated with Intestinal Immune-Inflammatory mRNA Expression and Plasmatic Acute Phase Proteins</title><p>Raw data regarding bioluminescence intensity (BLI) following euthanasia of all the animals were weakly and positively correlated with <italic toggle="yes">Nos2</italic> and <italic toggle="yes">Tnfa</italic> mRNA expression (<italic toggle="yes">p</italic> &#8804; 0.05) (<xref rid="app1-ijms-24-06424" ref-type="app">Table S1</xref>). Low negative significant correlations were also observed for <italic toggle="yes">Tjp1</italic>, <italic toggle="yes">Tgfb1,</italic> and <italic toggle="yes">Vegfa.</italic> When stratifying by sex, it was observed that all these correlations, except <italic toggle="yes">Tnfa</italic>, were more marked in the male group. In contrast, in females, <italic toggle="yes">Il10</italic>, <italic toggle="yes">Il6,</italic> and <italic toggle="yes">Il1b1</italic> positively correlated with BLI. The correlation of BLI with anti-inflammatory/pro-inflammatory cytokine ratios was calculated to identify the major immunoinflammatory balance in each of the experimental scenarios we studied. All the ratios were weakly correlated with BLI and only significant in female animals (<xref rid="app1-ijms-24-06424" ref-type="app">Table S2</xref>), especially <italic toggle="yes">Il10/Il6</italic> and <italic toggle="yes">Il10/Il1b1</italic> ratios.</p><p>These correlations were then stratified by the colitis model, trial design, and sex. In the correlations of gene expression with the BLI from the experimental end point of the TNBS therapeutic model, only <italic toggle="yes">Tjp1</italic> showed a moderate negative correlation (<xref rid="ijms-24-06424-t001" ref-type="table">Table 1</xref>). However, females showed a strong positive significant correlation with <italic toggle="yes">Il1b1</italic>, <italic toggle="yes">Il6,</italic> and <italic toggle="yes">Tnfa</italic>, and with <italic toggle="yes">Il10/Il1b1</italic> and <italic toggle="yes">Tgfb1/Il1b1</italic> ratios (<xref rid="ijms-24-06424-t001" ref-type="table">Table 1</xref> and <xref rid="app1-ijms-24-06424" ref-type="app">Table S3</xref>). In contrast, in the TNBS-colitis preventive trial, no significant correlation was observed.</p><p>Regarding the DSS-colitis therapeutic design (<xref rid="ijms-24-06424-t001" ref-type="table">Table 1</xref> and <xref rid="app1-ijms-24-06424" ref-type="app">Table S3</xref>), BLI showed a moderate positive correlation with <italic toggle="yes">Il6</italic>, while <italic toggle="yes">Tgfb1</italic> and the <italic toggle="yes">Il10/Il1b1</italic>, <italic toggle="yes">Il10/Il6</italic>, <italic toggle="yes">Tgfb1/Il1b1</italic>, <italic toggle="yes">Tgfb1/Il6,</italic> and <italic toggle="yes">Tgfb1/Tnfa</italic> ratios correlated in the opposite way. However, the strongest correlations were those recorded in males between BLI and <italic toggle="yes">Tgfb1</italic>, <italic toggle="yes">Vegfa,</italic> and <italic toggle="yes">Il10/Tnfa</italic> ratio (Rho &#8804; &#8722;0.60). In contrast, in female animals, there were no significant correlations at all. Furthermore, in the DSS preventive test, the most noticeable correlations were with <italic toggle="yes">Tjp1</italic> in females (Rho = 0.61) and with <italic toggle="yes">Hif1a</italic> in males (Rho = &#8722;0.54), as well as with the <italic toggle="yes">Tgfb1/Il6</italic> ratio.</p><p>Regarding the acute phase proteins (APPs), significant correlations with BLI were observed for CRP in the TNBS preventive trial (Rho = &#8722;0.42) and for SAA in the DSS therapeutic trial (Rho = 0.64). After separating the groups by sex, there was no significant correlation by model or design (<xref rid="ijms-24-06424-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec2dot3-ijms-24-06424"><title>2.3. Therapeutic Monitoring Response by Bioluminescence and Macroscopic Evaluations Shows Differences between Colitis Models, Experimental Trials, and Mouse Sex</title><p>Colitis monitoring by bioluminescence has made it possible to study the effects of drugs on the time course of colitis. Both treatments attenuated inflammatory activity as captured by ROS-induced bioluminescence in the TNBS therapeutic trial compared to untreated colitic mice (<xref rid="ijms-24-06424-f001" ref-type="fig">Figure 1</xref>A,B). Specifically, MTADV treatment was more efficient than dexamethasone because the reduction in the bioluminescent signal occurred earlier and lasted longer, mainly in male mice, whereas female mice responded better to dexamethasone. This MTADV-induced decrease in the bioluminescent signal in males concurs with an increase in body weight (<xref rid="ijms-24-06424-f003" ref-type="fig">Figure 3</xref>A), whereas the effects of dexamethasone consisted mainly of significantly decreasing the spleen weight, adherences, and the Wallace score (<xref rid="ijms-24-06424-f003" ref-type="fig">Figure 3</xref>B), with no differences between sexes (<xref rid="app1-ijms-24-06424" ref-type="app">Table S4</xref>). In contrast, there were no significant BLI changes when the treatments were given preventatively (<xref rid="ijms-24-06424-f001" ref-type="fig">Figure 1</xref>A); but both drugs tended to decrease body weight, especially in females treated with MTADV, as seen in the table in <xref rid="ijms-24-06424-f003" ref-type="fig">Figure 3</xref>A. Additionally, they significantly reduced the number of intestinal strictures (<xref rid="ijms-24-06424-f003" ref-type="fig">Figure 3</xref>B), which were more pronounced in dexamethasone females and MTADV males (<xref rid="app1-ijms-24-06424" ref-type="app">Table S4</xref>).</p><p>In the DSS therapeutic trial, only dexamethasone-treated females were able to significantly decrease BLI at any time-point in the inflammatory course (<xref rid="ijms-24-06424-f002" ref-type="fig">Figure 2</xref>A,B). Moreover, MTADV worked better in females than males, as shown in the table in <xref rid="ijms-24-06424-f002" ref-type="fig">Figure 2</xref>A. Unexpectedly, MTADV treatment caused an increase in body weight from the start of therapy in this model and design (<xref rid="ijms-24-06424-f004" ref-type="fig">Figure 4</xref>A), and this effect was even more marked in females (see the table in <xref rid="ijms-24-06424-f004" ref-type="fig">Figure 4</xref>A). The remaining macroscopic assessments (<xref rid="ijms-24-06424-f004" ref-type="fig">Figure 4</xref>B) showed results similar to those achieved for dexamethasone in TNBS colitis (<xref rid="ijms-24-06424-f003" ref-type="fig">Figure 3</xref>B), with a significant decrease in intestinal adherences and spleen weight. Furthermore, therapeutic administration of MTADV reduced the Wallace score compared to untreated DSS-colitis mice (<xref rid="ijms-24-06424-f004" ref-type="fig">Figure 4</xref>B), and this was more marked in the female group (<xref rid="app1-ijms-24-06424" ref-type="app">Table S4</xref>). Although both treatments given preventively significantly reduced the BLI signal regardless of sex (<xref rid="ijms-24-06424-f002" ref-type="fig">Figure 2</xref>A), only MTADV-treated mice showed resistance to weight loss, as occurs in dexamethasone-treated mice, and this effect is more marked in males (<xref rid="ijms-24-06424-f004" ref-type="fig">Figure 4</xref>A). MTADV treatment also decreased adherences in comparison to the other groups (<xref rid="ijms-24-06424-f004" ref-type="fig">Figure 4</xref>B), mainly in males (<xref rid="app1-ijms-24-06424" ref-type="app">Table S4</xref>).</p></sec><sec id="sec2dot4-ijms-24-06424"><title>2.4. Immune-Inflammatory Signatures in Experimental Colitis Drug Response</title><p>Regarding the TNBS therapeutic approach, MTADV increased <italic toggle="yes">Hif1a</italic>, <italic toggle="yes">Il1b1</italic>, <italic toggle="yes">Il6</italic>, <italic toggle="yes">Nos2</italic>, <italic toggle="yes">Tgfb1,</italic> and <italic toggle="yes">Tnfa</italic> expression (<xref rid="ijms-24-06424-f005" ref-type="fig">Figure 5</xref>A). By sex, this increase in expression upon MTADV was more remarkable in males (<xref rid="app1-ijms-24-06424" ref-type="app">Table S5</xref>). In the TNBS colitis prevention trial, <italic toggle="yes">Hif1a</italic> and <italic toggle="yes">Tgfb1</italic> expression was elevated by MTADV as in the therapeutic trial, but it also caused an increase in <italic toggle="yes">Tnfa</italic>, <italic toggle="yes">Vegfa,</italic> and <italic toggle="yes">Il10</italic> (<xref rid="ijms-24-06424-f005" ref-type="fig">Figure 5</xref>B). Interestingly, preventive treatment with dexamethasone increased Il1b1 expression. When stratified by sex, all these differences except <italic toggle="yes">Tnfa</italic> were only significant in female animals. Additionally, only females showed an increase in dexamethasone <italic toggle="yes">Nos2</italic> and MTADV <italic toggle="yes">Il1b1</italic> (<xref rid="app1-ijms-24-06424" ref-type="app">Table S5</xref>). Comparing sexes, only <italic toggle="yes">Nos2</italic> was increased in male and MTADV-treated controls in comparison to females.</p><p>In the case of the therapeutic DSS assay, dexamethasone caused significant changes in decreasing <italic toggle="yes">Nos2</italic> and <italic toggle="yes">Tnfa</italic> expression, as well as an increase in <italic toggle="yes">Vegf1a</italic> mRNA levels, compared to the other groups (<xref rid="ijms-24-06424-f005" ref-type="fig">Figure 5</xref>C). In addition, MTADV decreased <italic toggle="yes">Hif1a</italic> and <italic toggle="yes">Tjp1</italic> in comparison to controls, which was especially evident in females (<xref rid="app1-ijms-24-06424" ref-type="app">Table S6</xref>). Moreover, dexamethasone was associated with a higher expression of <italic toggle="yes">Il6</italic> in females, while MTADV decreased the expression of <italic toggle="yes">Il10</italic> in males. In non-treated male mice, <italic toggle="yes">Nos2</italic> and <italic toggle="yes">Il1b1</italic> were more expressed, while female mice showed a higher expression of <italic toggle="yes">Tjp1</italic> and <italic toggle="yes">Vegfa</italic> (<xref rid="app1-ijms-24-06424" ref-type="app">Table S6</xref>). In the preventive trial with DSS-colitis, dexamethasone-induced an increase in <italic toggle="yes">Hif1a</italic> and <italic toggle="yes">Il6</italic>, and a decrease in <italic toggle="yes">Tjp1</italic> expression compared to controls, while <italic toggle="yes">Tgfb1</italic> and <italic toggle="yes">Vegfa</italic> expression was increased in the MTADV group, as well as <italic toggle="yes">Nos2</italic> and <italic toggle="yes">Tjp1</italic> in comparison to dexamethasone (<xref rid="ijms-24-06424-f005" ref-type="fig">Figure 5</xref>D). When stratifying animals by sex, the dexamethasone-induced increases, and the MTADV <italic toggle="yes">Nos2</italic> increment occurred mainly in the male group (<xref rid="app1-ijms-24-06424" ref-type="app">Table S6</xref>).</p><p>CRP and SAA plasma were also compared between treatments, and their level assessments only showed noteworthy results in DSS colitis (<xref rid="app1-ijms-24-06424" ref-type="app">Figure S1B</xref>). In dexamethasone-treated mice, CRP levels were statistically higher than in the other groups in the DSS therapeutic trial. When analyzing these results regarding sex, the difference between the dexamethasone and the control group was only significant in males, while the difference between the dexamethasone and MTADV group was significant in females (<xref rid="app1-ijms-24-06424" ref-type="app">Table S7</xref>). Plasma SAA levels were also higher in the prophylactic dexamethasone group (<xref rid="app1-ijms-24-06424" ref-type="app">Figure S1B</xref>). By sex, MTADV-treated male and dexamethasone-treated female mice had lower concentrations of SAA in the TNBS preventive trial and the DSS therapeutic trial, respectively (<xref rid="app1-ijms-24-06424" ref-type="app">Table S7</xref>).</p></sec><sec id="sec2dot5-ijms-24-06424"><title>2.5. Mechanism of Action Based on Co-Expression Interactive Networks</title><p>Correlations between study markers were evaluated in order to characterize the prevalent immunoinflammatory mechanism of action in each model of experimental colitis and describe the course of the inflammatory process. In the TNBS therapeutic approach (<xref rid="ijms-24-06424-t002" ref-type="table">Table 2</xref>, results above the diagonal division in the table are for the therapeutic approach), only significant positive correlations were observed. Among these, <italic toggle="yes">Il1b1</italic> with <italic toggle="yes">Il10</italic> and <italic toggle="yes">Tnfa</italic>; <italic toggle="yes">Il10</italic> with <italic toggle="yes">Nos2</italic> and <italic toggle="yes">Tnfa</italic>, and <italic toggle="yes">Il6</italic> with <italic toggle="yes">Tgfb1</italic> stood out (0.6 &lt; Rho &lt; 0.9). <xref rid="ijms-24-06424-t002" ref-type="table">Table 2</xref> shows the remaining, less marked correlations. When stratifying by sex, many of the strongest correlations observed in all the animals remained, but there were other exclusive correlations in each sex group (<xref rid="app1-ijms-24-06424" ref-type="app">Tables S8 and S9</xref>, females, and males, respectively). This was the case of males, which showed a highlighted co-expression of <italic toggle="yes">Tgfb1</italic>, <italic toggle="yes">Tnfa</italic>, <italic toggle="yes">Vegfa,</italic> and <italic toggle="yes">Tjp1</italic> with <italic toggle="yes">Il6</italic>. In the preventive approach, correlations are mostly highly positive (0.6 &lt; Rho &lt; 0.9). <italic toggle="yes">Hif1a</italic> correlates with all the markers, mostly with <italic toggle="yes">Tgfb1</italic> and <italic toggle="yes">Vegfa</italic> (<xref rid="ijms-24-06424-t002" ref-type="table">Table 2</xref>, results below the diagonal division in the table are for the preventive approach). <italic toggle="yes">Il1b1</italic> also creates a positive network with all the markers except <italic toggle="yes">Il10</italic>, showing a Rho = 0.9 with <italic toggle="yes">Il6</italic>. Similarly, <italic toggle="yes">Tnfa</italic>, <italic toggle="yes">Vegfa,</italic> and <italic toggle="yes">Il6</italic> also show a positive correlation network with many markers. These co-expression profiles were very similar in males and females (<xref rid="app1-ijms-24-06424" ref-type="app">Tables S8 and S9</xref>).</p><p>On the other hand, in the DSS therapeutic approach, there were two remarkable correlations: <italic toggle="yes">Tjp1</italic> and <italic toggle="yes">Vegfa</italic> (which, at the same time, were negatively correlated with <italic toggle="yes">Nos2</italic> and <italic toggle="yes">Tnfa</italic>) (<xref rid="ijms-24-06424-t003" ref-type="table">Table 3</xref>, results above the diagonal division in the table are for the therapeutic approach) and <italic toggle="yes">Nos2</italic> and <italic toggle="yes">Tnfa</italic> (in connection with <italic toggle="yes">Il6</italic> and <italic toggle="yes">Il1b1</italic>). Most correlations also appeared in females and males (<xref rid="app1-ijms-24-06424" ref-type="app">Tables S10 and S11</xref>, respectively). Nevertheless, correlations corresponding to <italic toggle="yes">Hif1a</italic> with <italic toggle="yes">Tgfb1</italic>, <italic toggle="yes">Tnfa,</italic> and <italic toggle="yes">Il1b1</italic>, and the negative correlation of <italic toggle="yes">Nos2</italic> and <italic toggle="yes">Il6</italic> were exclusive to females. In the preventive approach, <italic toggle="yes">Tjp1</italic> had a moderate negative correlation with <italic toggle="yes">Il10</italic>. In contrast, <italic toggle="yes">Tgfb1</italic> and <italic toggle="yes">Il1b1</italic> were highly positively correlated to each other, and to <italic toggle="yes">Hif1a</italic> and <italic toggle="yes">Il6</italic>, and to a lesser extend to <italic toggle="yes">Tnfa</italic>, <italic toggle="yes">Vegfa,</italic> and <italic toggle="yes">Il1b1</italic> (<xref rid="ijms-24-06424-t003" ref-type="table">Table 3</xref>; results below the diagonal division in the table are for the preventive approach). Most of these significant correlations were only directly present in males after analyzing both sexes separately (<xref rid="app1-ijms-24-06424" ref-type="app">Table S11</xref>). However, females showed a high negative exclusive correlation of <italic toggle="yes">Il6</italic> with <italic toggle="yes">Vegfa</italic> (<xref rid="app1-ijms-24-06424" ref-type="app">Table S10</xref>).</p><p>Regarding the APPs&#8217; correlation to mRNA markers, there were moderate positive correlations between CRP levels and <italic toggle="yes">Il6</italic>, <italic toggle="yes">Hif1a,</italic> and <italic toggle="yes">Il1b1</italic> expression in both trials with DSS-induced colitis (<xref rid="app1-ijms-24-06424" ref-type="app">Table S12</xref>). Most of these significant correlations were maintained in females, who also provided additional and stronger correlations between CPR and <italic toggle="yes">Tjp1</italic> and <italic toggle="yes">Nos2</italic> (Rho &#8805; |0.84|) (<xref rid="app1-ijms-24-06424" ref-type="app">Table S13</xref>), although it should be noted that both sexes <italic toggle="yes">Vegfa</italic> showed a significant correlation with CRP levels. Regarding SAA plasma levels, strong positive correlations with <italic toggle="yes">Il6</italic> and <italic toggle="yes">Il1b1</italic> stand out both in the TNBS-colitis prevention trial and in the DSS-colitis therapeutic trial (<xref rid="app1-ijms-24-06424" ref-type="app">Table S12</xref>). These latter correlations were maintained mainly in females (<xref rid="app1-ijms-24-06424" ref-type="app">Table S13</xref>), who additionally displayed a strong positive correlation with <italic toggle="yes">Vegfa</italic> and <italic toggle="yes">Tjp1</italic>, and a negative correlation with <italic toggle="yes">Nos2</italic> in therapeutic DSS-colitis and positive ones with <italic toggle="yes">Nos2</italic> and <italic toggle="yes">Tnfa</italic> in preventive TNBS-colitis (<xref rid="app1-ijms-24-06424" ref-type="app">Table S13</xref>). Finally, note that the TNBS colitis model also showed strong negative correlations between SAA and <italic toggle="yes">Il6</italic> in females and <italic toggle="yes">Vegfa</italic> or <italic toggle="yes">Nos2</italic> in males.</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-24-06424"><title>3. Discussion</title><p>IBD is a complex disease with multifactorial pathogenesis whose mechanisms are not fully understood as yet. In vivo, experimental models are a useful tool for investigating its pathophysiology and for testing new therapies. To date, it has not been usual to include more than one model of colitis in studies. However, many studies have considered this to take into account different inflammatory phenotypes and colitis courses [<xref rid="B11-ijms-24-06424" ref-type="bibr">11</xref>,<xref rid="B36-ijms-24-06424" ref-type="bibr">36</xref>,<xref rid="B37-ijms-24-06424" ref-type="bibr">37</xref>,<xref rid="B38-ijms-24-06424" ref-type="bibr">38</xref>,<xref rid="B39-ijms-24-06424" ref-type="bibr">39</xref>,<xref rid="B40-ijms-24-06424" ref-type="bibr">40</xref>,<xref rid="B41-ijms-24-06424" ref-type="bibr">41</xref>,<xref rid="B42-ijms-24-06424" ref-type="bibr">42</xref>]. In this line, this study used two colitis mouse models, TNBS and DSS, considering their already established immune differences [<xref rid="B21-ijms-24-06424" ref-type="bibr">21</xref>]. By working on these two different preclinical models with two drug administration strategies (therapeutic and preventive) and sex parity, we built up different immunoinflammatory scenarios linked to the therapeutic response.</p><p>In this work, mice with the genetic background C57BL/6 were used to apply a proper chemical colitis inducer dosage. Specifically, this strain shows some features that make the mice more resistant to TNBS-induced colitis but more sensitive to DSS induction [<xref rid="B43-ijms-24-06424" ref-type="bibr">43</xref>]. A bioimaging time-course monitoring was used to study the intestinal inflammatory process in a longitudinal view. This method was further validated by relating the BLI to the quantification of inflammatory molecular signatures in both intestinal mucosa and systemic blood. Widely used macroscopic evaluations, a bioluminescent approach, and molecular assessments allowed us to establish the variability between and within the in vivo models in the drug testing of two different treatments, one being dexamethasone, a widely used treatment in IBD, and the other being MTADV, an experimental treatment and an inhibitor of SAA [<xref rid="B44-ijms-24-06424" ref-type="bibr">44</xref>].</p><p>The follow-up of the colitis time course was performed by capturing ROS production using the L-012 probe in the chemically-induced colitis models. ROS production in the colonic mucosa of experimental colitis models has been correlated with colitis severity [<xref rid="B35-ijms-24-06424" ref-type="bibr">35</xref>,<xref rid="B45-ijms-24-06424" ref-type="bibr">45</xref>,<xref rid="B46-ijms-24-06424" ref-type="bibr">46</xref>]. Real-time in vivo bioluminescence made it possible to quantify the colitis course at each time point and to track intra-individual variability. This meant a reduction in the number of animals per group and a great experimental refinement in monitoring the bowel inflammation time-course of TNBS and DSS colitis models. The inflammatory courses shaped by the BLI of controls matched with what is described in the literature. The bioluminescent images from the TNBS-induced models showed two inflammatory outbreaks. There was a first outbreak probably matching innate immunity cells, mainly neutrophils and macrophages, despite the coexistence of caustic effects of the TNBS enema during this acute phase [<xref rid="B47-ijms-24-06424" ref-type="bibr">47</xref>,<xref rid="B48-ijms-24-06424" ref-type="bibr">48</xref>]. In the DSS, there was immunosuppression immediately after DSS withdrawal until two days later, when a single inflammatory flare was detected by increasing the intensity of ROS-induced bioluminescence, probably matching an innate immune response [<xref rid="B49-ijms-24-06424" ref-type="bibr">49</xref>].</p><p>ROS-induced bioluminescence signals positively correlated with the intestinal expression of <italic toggle="yes">Nos2</italic>, although this correlation was more apparent in male animals. <italic toggle="yes">Nos2</italic> encodes for the inducible form of the nitric oxide synthase enzyme, which is responsible for the synthesis of the free radical nitric oxide (NO) from neutrophils and macrophages after microbes or cytokines activate NF&#954;B [<xref rid="B50-ijms-24-06424" ref-type="bibr">50</xref>]. NO production has been related to Th1 and Th17 cytokines and has been positively correlated with pro-inflammatory cytokines in plasma in IBD [<xref rid="B51-ijms-24-06424" ref-type="bibr">51</xref>,<xref rid="B52-ijms-24-06424" ref-type="bibr">52</xref>]. To further refine this validation, we studied the association between BLI and the expression of different markers of oxidative stress and immune inflammation. Thus, specific correlation profiles were identified according to the experimental model and drug administration strategy. When mice were stratified by sex, correlations became more significant, with remarkable anti-inflammatory/pro-inflammatory ratios in female animals since they negatively correlated with BLI. In addition, certain signs of anti-inflammatory activity, mucosal barrier recoveries, and angiogenesis, such as <italic toggle="yes">Tgfb1</italic>, <italic toggle="yes">Vegfa,</italic> and <italic toggle="yes">Tjp1,</italic> were also negatively correlated only in male animals. Altogether, this suggests that the inflammatory processes driving ROS formation and, thus, BLI detection are highly dependent on sex. Specific inflammatory or reparation markers are therefore required to validate this in vivo imaging method (<xref rid="ijms-24-06424-t004" ref-type="table">Table 4</xref>).</p><p>Regarding drug screening, both models showed a BLI decrease associated with both treatments. These therapies induced specific changes in cytokine and oxidative stress markers that depended on the experimental model and sex of the animal. Additionally, most macroscopic morphometric data also matched with a decrease in BLI.</p><p>In the TNBS model, the therapeutic administration of dexamethasone produced a decrease in pro-inflammatory cytokines similar to that of IBD, such as <italic toggle="yes">Tnfa</italic>, <italic toggle="yes">Il1b1,</italic> and <italic toggle="yes">Il6</italic>, which matched what was observed in the BLI, contrary to an increase in SAA plasmatic levels. Nevertheless, in the preventive trial, dexamethasone established an inverse situation due to an increase in the relation <italic toggle="yes">Il1b1/Il10</italic>. The situation described above was more obvious in female animals. In contrast, MTADV treatment drove more changes in the male immune response. Here, there was an unexpected increment in pro-inflammatory cytokines and oxidation markers in both trials (<italic toggle="yes">Hif1a</italic> and <italic toggle="yes">Tnfa</italic>). Nevertheless, the treatment decreased the BLI in the therapeutic approach and increased reparation markers (<italic toggle="yes">Vegfa</italic> and <italic toggle="yes">Tgfb1</italic>) in the preventive design. In this trial, there was also a decrease in plasmatic levels of SAA, as expected due to the targeting action of MTADV [<xref rid="B44-ijms-24-06424" ref-type="bibr">44</xref>]. Similarly, in another study, MTADV showed contradictory results by reducing some inflammatory markers, such as SAA, while it increased IFN-&#947; in TNBS mice [<xref rid="B44-ijms-24-06424" ref-type="bibr">44</xref>]. Moreover, when looking at the correlations between mRNAs expressions and BLI, the above-mentioned <italic toggle="yes">Il1b1</italic>, <italic toggle="yes">Il6,</italic> and <italic toggle="yes">Tnfa</italic> showed a significant correlation (Rho &#8805; 0.60) with BLI, mainly in females, regardless of treatment.</p><p>In the DSS model, BLI was reduced in the drug-treated groups and more pronounced in prevention and exclusive to females in the therapeutic trial. In addition, dexamethasone produced a reduction in <italic toggle="yes">Nos2,</italic> mainly in males, as well as a <italic toggle="yes">Vegfa</italic> in the therapeutic trial. In fact, the pro-angiogenic VEGFA pathway was related to the mechanism of action within glucocorticoid response in a UC cohort [<xref rid="B53-ijms-24-06424" ref-type="bibr">53</xref>]. Furthermore, a decrease in <italic toggle="yes">Tnfa</italic> following the same trend as the BLI decrement was also seen in females. Both treatment strategies in DSS-colitis showed a loss in weight regardless of sex, which is contradictory to our understanding that glucocorticoids induce weight gain. Nevertheless, this fact is dose and time-dependent [<xref rid="B54-ijms-24-06424" ref-type="bibr">54</xref>,<xref rid="B55-ijms-24-06424" ref-type="bibr">55</xref>], and our experiment does not imply chronic exposure to this treatment. On the other hand, treatment with MTADV induced an increment in the expression of <italic toggle="yes">Nos2</italic> regardless of sex, while, in males, <italic toggle="yes">Tnfa,</italic> among others, was increased, showing a pro-inflammatory profile. This matched with a decrease in the BLI in females but not in males in the therapeutic approach. Nevertheless, males showed strong negative correlations linking bioluminescent signals with a decrease in reparation and healing processes (rho = &#8722;0.60 and &#8722;0.81 for <italic toggle="yes">Tgfb1</italic> and <italic toggle="yes">Vegfa</italic>, respectively), whose indicators are the most affected by treatments.</p><p>The dexamethasone results show great differences between the sexes. It is known that there are sex-dependent differences in response to glucocorticoids. Recently, a study observed an overrepresentation of transcriptomic targets of the glucocorticoid receptor pathway in DSS colitis [<xref rid="B27-ijms-24-06424" ref-type="bibr">27</xref>]. It is known that females exert more potent pro-inflammatory processes due to significantly higher estrogen liberation and a lower presence of androgens than males, these being pro-inflammatory and anti-inflammatory, respectively [<xref rid="B56-ijms-24-06424" ref-type="bibr">56</xref>]. In line with this, we found higher <italic toggle="yes">Tnfa</italic> levels in females in the TNBS-colitis model compared to male controls in the therapeutic approach. In fact, glucocorticoids can inhibit the action of these hormones, suggesting that sex is an important point to check whenever glucocorticoids are used as treatment [<xref rid="B56-ijms-24-06424" ref-type="bibr">56</xref>]. There is also a general increase in <italic toggle="yes">Il6</italic> [<xref rid="B57-ijms-24-06424" ref-type="bibr">57</xref>,<xref rid="B58-ijms-24-06424" ref-type="bibr">58</xref>] in DSS colitis in male animals in the therapeutic trial. Actually, the role of IL-6 has been reported to be sex-dependent in many diseases and situations [<xref rid="B24-ijms-24-06424" ref-type="bibr">24</xref>].</p><p>Comparing both models, we found that females responded better to dexamethasone in TNBS than in the DSS model. As for males, an inverse situation is observed. MTADV treatment worked better in males with TNBS-induced colitis and females with DSS-induced colitis, highlighting the potential importance of using different animal models and both sexes in drug screening studies. In addition, while poor results were obtained in the preventive trial with TNBS, many inflammatory clinical and molecular markers were decreased in the DSS model. These results rely on the difference in the pattern of administration of the inductor of colitis. The fact that the preventive treatments started while DSS was being given to the animal may explain why the preventive treatment worked. Although the inflammatory process was ongoing in these stages, the drivers of this process may have been inhibited, and further inflammation was precluded. Moreover, in the TNBS preventive trial, we did not observe many changes in cytokines with the treatments nor a correlation between these markers and BLI. The TNBS acute phase might be confounded with a caustic reaction to the chemical itself [<xref rid="B47-ijms-24-06424" ref-type="bibr">47</xref>,<xref rid="B48-ijms-24-06424" ref-type="bibr">48</xref>]. The increase in BLI might be a consequence of the production of ROS from the necrotizing effect of TNBS enema on intestinal epithelial cells.</p><p>In the TNBS colitis model, <italic toggle="yes">Tnfa</italic>, <italic toggle="yes">Il1b1,</italic> and <italic toggle="yes">Hif1a</italic>, the latter predominantly in the preventive trials, built interesting correlation networks, thereby highlighting the fact that they are the cytokines that drive the inflammatory process in female animals. In males, <italic toggle="yes">Tnfa</italic> and <italic toggle="yes">Il6</italic> were central cytokines, networking with other cytokines regardless of the treatment. In fact, <italic toggle="yes">Il6</italic> correlated with some T-regulatory cells (Treg), angiogenesis, and reparation processes. Moreover, regardless of the animal sex, the inflammatory <italic toggle="yes">Tnfa</italic>, <italic toggle="yes">Il6,</italic> and <italic toggle="yes">Il1b1</italic> correlated positively with BLI, as well as with systemic SAA. Indeed, this is consistent with the fact that these inflammatory cytokines are potent inducers of APPs in the liver [<xref rid="B59-ijms-24-06424" ref-type="bibr">59</xref>]. Hence, <italic toggle="yes">Tnfa</italic> becomes a central cytokine in the TNBS model, as also happens in CD [<xref rid="B60-ijms-24-06424" ref-type="bibr">60</xref>], regardless of the sex of the animal. This was also shown in the preventive approach. In fact, <italic toggle="yes">Tnfa</italic>, <italic toggle="yes">Il1b1,</italic> and <italic toggle="yes">Il6</italic> play a central role in TNBS colitis due to T cell, neutrophil, and macrophage infiltration [<xref rid="B21-ijms-24-06424" ref-type="bibr">21</xref>], as well as in T CD4+ differentiation to Th1 and Th17 cells as shown in <xref rid="ijms-24-06424-f006" ref-type="fig">Figure 6</xref>. Unfortunately, <italic toggle="yes">Il4</italic>, <italic toggle="yes">Il17a,</italic> and <italic toggle="yes">Ifng</italic> expressions were too low in our samples and precluded us from defining, more precisely, the immune profile of the intestinal mucosa. There is also prominent participation of <italic toggle="yes">Il10</italic> and <italic toggle="yes">Tgfb1</italic> in the immune networks of TNBS-colitis regardless of the trial and sex that counteracts the inflammatory imbalance [<xref rid="B21-ijms-24-06424" ref-type="bibr">21</xref>]. They induce na&#239;ve T lymphocytes to become Tregs (as shown in <xref rid="ijms-24-06424-f006" ref-type="fig">Figure 6</xref>). Our results match those obtained in the same model by Silva et al. 2022 [<xref rid="B61-ijms-24-06424" ref-type="bibr">61</xref>], and IL-10 therapy ameliorates TNBS colitis [<xref rid="B62-ijms-24-06424" ref-type="bibr">62</xref>]. Moreover, <italic toggle="yes">Vegfa</italic> was also correlated positively to <italic toggle="yes">Il10</italic> and <italic toggle="yes">Tgfb1</italic> networks and negatively to SAA, the latter in the therapeutic approach. <italic toggle="yes">Vegfa</italic> has been related to inflammation, angiogenesis, and leucocyte rolling in IBD [<xref rid="B63-ijms-24-06424" ref-type="bibr">63</xref>]. Finally, <italic toggle="yes">Hif1a</italic> also built interesting co-expression networks in the preventive approach linked to acute inflammation. In both human IBD [<xref rid="B64-ijms-24-06424" ref-type="bibr">64</xref>] and experimental colitis [<xref rid="B65-ijms-24-06424" ref-type="bibr">65</xref>,<xref rid="B66-ijms-24-06424" ref-type="bibr">66</xref>], hypoxia-induced HIF1A is critical for many mucosal barrier-protective genes and angiogenesis [<xref rid="B64-ijms-24-06424" ref-type="bibr">64</xref>].</p><p>In DSS-induced intestinal inflammation, mucosal <italic toggle="yes">Il6</italic> and plasmatic SAA correlated positively with BLI, while <italic toggle="yes">Tgfb1</italic> correlated negatively in the therapeutic approach. On the other hand, both BLI and <italic toggle="yes">Nos2</italic> correlated negatively with reparative <italic toggle="yes">Tjp1</italic> and <italic toggle="yes">Vegfa</italic> expression, mainly in females. In contrast, in the preventive trial, cytokine correlations were similar to those in the TNBS and mainly influenced by males. Here, there was also a negative correlation between <italic toggle="yes">Il6</italic> and BLI, suggesting a certain immunosuppressive effect in this acute inflammatory stage. This contrasts with the therapeutic model, in which reparatory processes were the protagonists. DSS-induced barrier weakness causes bacterial translocation, which activates functions driven by toll-like receptors in both epithelial cells and neutrophils [<xref rid="B21-ijms-24-06424" ref-type="bibr">21</xref>]. Among these is the synthesis of NFkB-induced cytokines, but also an expression of epithelial barrier genes and increasing endothelial permeability and adherence for neutrophil infiltration (<xref rid="ijms-24-06424-f006" ref-type="fig">Figure 6</xref>). Moreover, at the moment the mice were euthanized in the preventive trials, the APPs correlated with the pro-inflammatory markers that are their inducers [<xref rid="B59-ijms-24-06424" ref-type="bibr">59</xref>]. When <italic toggle="yes">Tnfa</italic> is increased, as in the DSS model, this factor reduces the expression of tight junction proteins, as already seen in IBD [<xref rid="B67-ijms-24-06424" ref-type="bibr">67</xref>,<xref rid="B68-ijms-24-06424" ref-type="bibr">68</xref>], and may also affect angiogenesis. A common feature in both approaches is <italic toggle="yes">Hif1a</italic> expression, which, as mentioned above, is related to IBD and DSS-induced colitis [<xref rid="B69-ijms-24-06424" ref-type="bibr">69</xref>,<xref rid="B70-ijms-24-06424" ref-type="bibr">70</xref>]. There were many important differences in sexes here, too. In fact, in the therapeutic approach, male controls showed more pro-inflammatory signals than females, whereas females showed more <italic toggle="yes">Tjp1</italic> and <italic toggle="yes">Vegfa</italic>. In addition, DSS causes a loss of reparatory response upon inflammation [<xref rid="B17-ijms-24-06424" ref-type="bibr">17</xref>], but this may happen mainly in male mice since they are more susceptible to DSS [<xref rid="B10-ijms-24-06424" ref-type="bibr">10</xref>], whereas females exert a higher reparatory response.</p></sec><sec id="sec4-ijms-24-06424"><title>4. Materials and Methods</title><sec id="sec4dot1-ijms-24-06424"><title>4.1. Mice</title><p>Ten- to twelve-week-old C57BL/6J mice (male and female) were purchased from Jackson Laboratory (Charles River; Barcelona, Spain). The mice were housed in the Germans Trias i Pujol Research Institute (IGTP) conventional facility, and the studies were conducted in compliance with animal research guidelines. All the experiments were approved by the Institutional Animal Care and Use Committee of the IGTP and authorized by the Catalan Government.</p></sec><sec id="sec4dot2-ijms-24-06424"><title>4.2. Chemically Induced IBD Models</title><p>The study was performed in two IBD models using TNBS and DSS as colitis inducers. For the TNBS colitis, mice were anesthetized using isoflurane, and then each mouse received an intrarectal enema of 3 mg TNBS dissolved in 100 mL of ethanol/H2O (50%/50%, <italic toggle="yes">v/v</italic>). In the case of DSS-induced colitis, mice received 2.5% DSS in drinking water for five consecutive days. Mice were euthanized at the specific times established according to the previous tests performed. The endpoints for the therapeutic trials of TNBS and DSS were on days seven and ten, respectively, and the endpoints for the preventive trials of TNBS and DSS were set on days three and seven, respectively.</p></sec><sec id="sec4dot3-ijms-24-06424"><title>4.3. Experimental Groups</title><p>In both models of experimental colitis, mice were randomly divided into four groups that remained constant along the different experimental designs: non-treated sham colitis group (healthy); TNBS/DSS colitis + vehicle (PBS, s.c); TNBS/DSS colitis + dexamethasone (1.5 mg * kg<sup>&#8722;1</sup>, s.c.); and TNBS/DSS colitis + MTADV (3 mg * kg<sup>&#8722;1</sup>, s.c.); Drug doses were chosen according to bibliographic criteria and previous dose-response screenings in both experimental models. Each group included ten animals (half of which were females).</p><p>In the therapeutic assay, PBS, dexamethasone, or MTADV were administered by subcutaneous injection from day four after intrarectal instillation of TNBS and were continued until day seven (<xref rid="ijms-24-06424-f007" ref-type="fig">Figure 7</xref>A). In vivo real-time bioluminescence was performed from 48 h to day seven of the TNBS course. To evaluate the potential preventive effect of the drugs in the TNBS group, mice received PBS or each drug from three days from &#8722;48 h to day zero before TNBS instillation (<xref rid="ijms-24-06424-f007" ref-type="fig">Figure 7</xref>B). Bioimaging was performed at baseline (before TNBS administration) and at 24, 48, and 72 h after TNBS or sham colitis induction.</p><p>In the therapeutic approach, the treatments were distributed in four subcutaneous doses of PBS, dexamethasone, or MTADV dispensed between days seven and ten (<xref rid="ijms-24-06424-f007" ref-type="fig">Figure 7</xref>C). Bioimaging was performed at the pre-colitis stage (day &#8722;1) and from day five to day ten. In the preventive DSS-colitis trial, mice received three drug doses, during the last three days of DSS administration, from day three to day five (<xref rid="ijms-24-06424-f007" ref-type="fig">Figure 7</xref>D). Bioimaging was performed at the pre-colitis stage (day &#8722;1) and from day five to day seven.</p></sec><sec id="sec4dot4-ijms-24-06424"><title>4.4. Real-Time In Vivo ROS Quantification by Bioluminescent Imaging</title><p>Mice were anesthetized by isoflurane and injected with probe L-012 at 25 mg * kg<sup>&#8722;1</sup> (i.v.) via the retro-orbital sinus, which produces a chemiluminescent signal when reacting to ROS [<xref rid="B32-ijms-24-06424" ref-type="bibr">32</xref>]. Image acquisition was performed with the IVIS Lumina II imaging system (PerkinElmer Imaging Systems, Waltham, MA, USA). Region of interest (ROI) was measured using Living Image software 4.7.2 and expressed as average radiance (photons/second/cm<sup>2</sup>/sr). A baseline image was taken before colitis induction (background), and the colitis time course was followed, capturing images at previously selected time points (<xref rid="ijms-24-06424-f007" ref-type="fig">Figure 7</xref>A&#8211;7D). The bioluminescence images were normalized using the baseline values of each mouse as background and expressing their values as FC. In the therapeutic trials, another FC calculation was added with the mean values of the days between the start of the colitis and the treatment to evaluate the treatment effect.</p></sec><sec id="sec4dot5-ijms-24-06424"><title>4.5. Sampling and Macroscopic Colitis Evaluation</title><p>Animals were weighed, and their well-being was assessed daily during the experimental time course. After euthanasia, plasma samples were obtained, and the colon and spleen were dissected and weighed. The colonic weight/length ratio, the number of colonic strictures, and hyperemia were measured. These macroscopic features were grouped and evaluated together according to the Wallace score (<xref rid="app1-ijms-24-06424" ref-type="app">Table S14</xref>) [<xref rid="B71-ijms-24-06424" ref-type="bibr">71</xref>]. RNAlater-preserved colonic tissue and plasma samples were kept frozen at &#8722;80&#176;.</p></sec><sec id="sec4dot6-ijms-24-06424"><title>4.6. Quantitative Real-Time Polymerase Chain Reaction</title><p>Colon samples in RNA were later thawed and washed with PBS, and fragmented using a mortar cooled in liquid nitrogen. Then, 25 mg of frozen tissue was homogenized in 700 ul of QIAzol reagent (QIAgen, Madrid, Spain) using a gentleMACS&#8482; tissue dissociator (Miltenyi Biotech, Teterow, Germany). After chloroform was added, the sample was separated into three phases. The upper phase was then used for RNA purification using the <italic toggle="yes">miRNeasy</italic> Mini kit in the QIAcube system (QIAGEN, Hilden, Germany) following the manufacturer&#8217;s protocol. RNA integrity was evaluated by an electrophoresis system Agilent 6000 Nano kit (Agilent Technologies, Santa Clara, CA, USA) using RNA Bioanalyzer chips. Only RNA integrity numbers equal to or higher than 6.5 were deemed good and processed. A total of 1 &#956;g of total RNA was retrotranscribed to cDNA using the PrimeScriptTM RT reagent (Perfect Real Time kit; Takara, Shiga, Japan) following the manufacturer&#8217;s instructions. TaqMan<sup>&#174;</sup>Assays (ThermoFisher Scientific, Madrid, Spain) for qRT-PCR of <italic toggle="yes">Il6</italic>, <italic toggle="yes">Il10</italic>, <italic toggle="yes">Tgfb1</italic>, <italic toggle="yes">Tnfa</italic>, <italic toggle="yes">Vegfa</italic>, <italic toggle="yes">Hif1a</italic>, <italic toggle="yes">Nos2</italic>, <italic toggle="yes">Il1b1</italic> and <italic toggle="yes">Tjp1</italic> (TaqMan probes: Mm00446190_m1, Mm00439614_m1, Mm01178820_m1, Mm00443260_g1, Mm00437306_m1, Mm00468869_m1, Mm00440502_m1, Mm00434228_m1, and Mm01320638_m1, respectively) were used. PCR thermal cycling included initial denaturing at 95 &#176;C for 10 s, 40 cycles of 95 &#176;C for 15 s, and 60 &#176;C for one minute (LightCycler480 system; Roche Diagnostics, Basel, Switzerland). Data from qRT-PCR were calculated using the 2<sup>&#8722;&#916;&#916;Ct</sup> method [<xref rid="B72-ijms-24-06424" ref-type="bibr">72</xref>]. The results were normalized with both <italic toggle="yes">Gapdh</italic> and <italic toggle="yes">B2m</italic> (Mm99999915_g1 and Mm00437762_m1, respectively) housekeeping genes.</p></sec><sec id="sec4dot7-ijms-24-06424"><title>4.7. Enzyme-Linked Immunosorbent Assay</title><p>Plasma samples were thawed, vortexed, and centrifuged for 10 min at 1000 rpm. C-Reactive Protein (CRP) plasma levels were measured using the Mouse CRP ELISA Kit (Invitrogen by Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer&#8217;s instructions, diluting all samples 2000-fold. Serum amyloid antigen (SAA) plasmatic concentrations were determined using the Phase SAA Murine Assay Kit (Tridelta Development Ltd., Maynooth, Ireland), diluting the samples between 50&#8211;100-fold for the TNBS-colitis and 500&#8211;8000-fold for DSS-colitis. All samples were analyzed in duplicates, and OD was measured in the Varioskan microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). Standard curves were generated. For the CRP quantification, a four-parameter algorithm in the MyCurveFit Add-in in Microsoft Excel 2016 software (version R2 v1.0102.823, MyAssays Ltd, Brighton, United Kingdom).</p></sec><sec id="sec4dot8-ijms-24-06424"><title>4.8. Statistics</title><p>All quantitative data were checked for normality using a Shapiro-Wilk test. We also applied the Mann&#8211;Whitney U test in pairwise comparisons between different animal groups at the same time point. The comparisons of the qRT-PCR and ELISA data between treatment groups and sexes were performed with the Kruskal&#8211;Wallis test with a post hoc Dunn&#8217;s test analysis or a Mann&#8211;Whitney U test. Comparisons with <italic toggle="yes">p</italic> &#8804; 0.05 were significant statistically. Correlation analyses were performed using Spearman&#8217;s test. Correlations with 0.20 &#8804; Rho &lt; 0.40 were considered weak, those with 0.40 &#8804; Rho &lt; 0.60 moderate, and those with Rho &#8804; 0.60 strong. All these analyses were performed with R software version 4.2.0.</p></sec></sec><sec sec-type="conclusions" id="sec5-ijms-24-06424"><title>5. Conclusions</title><p>Preventive MTADV induces reparatory activity in both models, even though it induces inflammation when used as treatment. However, dexamethasone plays a more remarkable role in therapy, mainly in the DSS model, by decreasing inflammatory factors. Nevertheless, these results are highly dependent on the sex of the animal. We, therefore, conclude that the use of the TNBS and DSS experimental colitis models is a suitable strategy for evaluating the pathology of IBD and drug screening. However, features such as the variability between individuals of each group and the sex of the animal should be considered and can be solved by using the BLI or including both sexes in the groups. In addition, the immunity of each type of model and the course of the inflammation must be taken into account depending on the molecular focus of the study.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to Raquel Pluvinet and Lauro Sumoy of the High Content Genomics and Bioinformatics Unit in the IGTP for their support in RNA quality control. We would also like to acknowledge the collaboration of the IGTP-Centre de Medicina Comparativa i Bioimatge (CMCiB) team for the control and management of the entire in vivo study and the Benjamin Santos and Jordi Armengol for pharmacological advice. We also want to acknowledge Laura Clua and Carolina Serena for their advice during the study development.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-ijms-24-06424"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/ijms24076424/s1">https://www.mdpi.com/article/10.3390/ijms24076424/s1</uri>.</p><supplementary-material id="ijms-24-06424-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ijms-24-06424-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, J.M.; writing&#8212;original draft preparation, R.S., C.B. and K.S.; writing&#8212;review and editing, J.M., E.D., R.B., P.V. and R.S.; in vivo experiments, A.G., V.L., A.G.-J. and R.S.; molecular biology assays, C.B., K.S., A.P., M.L., E.J.-O. and R.S.; statistics and a graphical representation, A.G., A.P., C.B., K.S., M.L. and R.S.; supervision and project administration, J.M.; funding acquisition, E.D. and M.M.; J.M. designed and conducted the study. All authors have made a final critical review of this article. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol was approved by the Ethics Committee of Generalitat de Catalunya: Departament de Territori i Sostenibilitat Direcci&#243; General de Pol&#237;tiques Ambientals i Medi Natural (approval code: 9933; date: 06/06/2018). </p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">APP</td><td align="left" valign="middle" rowspan="1" colspan="1">Acute Phase Protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BLI</td><td align="left" valign="middle" rowspan="1" colspan="1">Bioluminescence intensity</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRP</td><td align="left" valign="middle" rowspan="1" colspan="1">C-Reactive Protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DSS</td><td align="left" valign="middle" rowspan="1" colspan="1">Dextran sulphate sodium</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ELISA</td><td align="left" valign="middle" rowspan="1" colspan="1">Enzyme-linked immunosorbent assay</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FC</td><td align="left" valign="middle" rowspan="1" colspan="1">Fold-change</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IBD</td><td align="left" valign="middle" rowspan="1" colspan="1">Inflammatory Bowel Diseases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MPO</td><td align="left" valign="middle" rowspan="1" colspan="1">Myeloperoxidase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MTADV</td><td align="left" valign="middle" rowspan="1" colspan="1">5-MER peptide methionine-threonine-alanine-aspartic acid-valine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCR</td><td align="left" valign="middle" rowspan="1" colspan="1">Polymerase chain reaction</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">qRT</td><td align="left" valign="middle" rowspan="1" colspan="1">quantitative real-time</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ROS</td><td align="left" valign="middle" rowspan="1" colspan="1">Reactive Oxygen Species</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SAA</td><td align="left" valign="middle" rowspan="1" colspan="1">Serum Amyloid Antigen</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Th</td><td align="left" valign="middle" rowspan="1" colspan="1">T-helper</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNBS</td><td align="left" valign="middle" rowspan="1" colspan="1">2,4,6-trinitrobenzenesulfonic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Treg</td><td align="left" valign="middle" rowspan="1" colspan="1">T-regulatory cell</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-ijms-24-06424"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roda</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chien Ng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kotze</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Argollo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Panaccione</surname><given-names>R.</given-names></name><name name-style="western"><surname>Spinelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kaser</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peyrin-Biroulet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Danese</surname><given-names>S.</given-names></name></person-group><article-title>Crohn&#8217;s Disease</article-title><source>Nat. Rev. Dis. Prim.</source><year>2020</year><volume>6</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1038/s41572-020-0156-2</pub-id><pub-id pub-id-type="pmid">32242028</pub-id></element-citation></ref><ref id="B2-ijms-24-06424"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>T.</given-names></name></person-group><article-title>Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches</article-title><source>Gastrointestinal Pharmacology</source><publisher-name>Springer</publisher-name><publisher-loc>Boston, MA, USA</publisher-loc><year>2017</year><fpage>115</fpage><lpage>146</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/164_2016_122</pub-id><pub-id pub-id-type="pmid">28233184</pub-id></element-citation></ref><ref id="B3-ijms-24-06424"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mehandru</surname><given-names>S.</given-names></name><name name-style="western"><surname>Colombel</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Peyrin-Biroulet</surname><given-names>L.</given-names></name></person-group><article-title>Crohn&#8217;s Disease</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>1741</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31711-1</pub-id><pub-id pub-id-type="pmid">27914655</pub-id></element-citation></ref><ref id="B4-ijms-24-06424"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popov</surname><given-names>J.</given-names></name><name name-style="western"><surname>Caputi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nandeesha</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Pai</surname><given-names>N.</given-names></name></person-group><article-title>Microbiota-Immune Interactions in Ulcerative Colitis and Colitis Associated Cancer and Emerging Microbiota-Based Therapies</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>11365</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222111365</pub-id><pub-id pub-id-type="pmid">34768795</pub-id><pub-id pub-id-type="pmcid">PMC8584103</pub-id></element-citation></ref><ref id="B5-ijms-24-06424"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Annese</surname><given-names>V.</given-names></name></person-group><article-title>Genetics and Epigenetics of IBD</article-title><source>Pharmacol. Res.</source><year>2020</year><volume>159</volume><fpage>104892</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104892</pub-id><pub-id pub-id-type="pmid">32464322</pub-id></element-citation></ref><ref id="B6-ijms-24-06424"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caballol</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gudi&#241;o</surname><given-names>V.</given-names></name><name name-style="western"><surname>Panes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salas</surname><given-names>A.</given-names></name></person-group><article-title>Ulcerative Colitis: Shedding Light on Emerging Agents and Strategies in Preclinical and Early Clinical Development</article-title><source>Expert Opin. Investig. Drugs</source><year>2021</year><volume>30</volume><fpage>931</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1080/13543784.2021.1965122</pub-id><pub-id pub-id-type="pmid">34365869</pub-id></element-citation></ref><ref id="B7-ijms-24-06424"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keubler</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Buettner</surname><given-names>M.</given-names></name><name name-style="western"><surname>H&#228;ger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bleich</surname><given-names>A.</given-names></name></person-group><article-title>A Multihit Model</article-title><source>Inflamm. Bowel Dis.</source><year>2015</year><volume>21</volume><fpage>1967</fpage><lpage>1975</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000000468</pub-id><pub-id pub-id-type="pmid">26164667</pub-id><pub-id pub-id-type="pmcid">PMC4511684</pub-id></element-citation></ref><ref id="B8-ijms-24-06424"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ostanin</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koboziev</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>L.</given-names></name><name name-style="western"><surname>Robinson-Jackson</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Kosloski-Davidson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Price</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Grisham</surname><given-names>M.B.</given-names></name></person-group><article-title>T Cell Transfer Model of Chronic Colitis: Concepts, Considerations, and Tricks of the Trade</article-title><source>Am. J. Physiol. Liver Physiol.</source><year>2009</year><volume>296</volume><fpage>G135</fpage><lpage>G146</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.90462.2008</pub-id><pub-id pub-id-type="pmcid">PMC2643911</pub-id><pub-id pub-id-type="pmid">19033538</pub-id></element-citation></ref><ref id="B9-ijms-24-06424"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waldner</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Neurath</surname><given-names>M.F.</given-names></name></person-group><article-title>Chemically Induced Mouse Models of Colitis</article-title><source>Curr. Protoc. Pharmacol.</source><year>2009</year><volume>46</volume><fpage>5</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1002/0471141755.ph0555s46</pub-id><pub-id pub-id-type="pmid">22294401</pub-id></element-citation></ref><ref id="B10-ijms-24-06424"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wirtz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Popp</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kindermann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gerlach</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weigmann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fichtner-Feigl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Neurath</surname><given-names>M.F.</given-names></name></person-group><article-title>Chemically Induced Mouse Models of Acute and Chronic Intestinal Inflammation</article-title><source>Nat. Protoc.</source><year>2017</year><volume>12</volume><fpage>1295</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1038/nprot.2017.044</pub-id><pub-id pub-id-type="pmid">28569761</pub-id></element-citation></ref><ref id="B11-ijms-24-06424"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lor&#233;n</surname><given-names>V.</given-names></name><name name-style="western"><surname>Many&#233;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fuentes</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Cabr&#233;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ojanguren</surname><given-names>I.</given-names></name><name name-style="western"><surname>Espadaler</surname><given-names>J.</given-names></name></person-group><article-title>Comparative Effect of the I3.1 Probiotic Formula in Two Animal Models of Colitis</article-title><source>Probiot. Antimicrob. Proteins</source><year>2017</year><volume>9</volume><fpage>71</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1007/s12602-016-9239-5</pub-id><pub-id pub-id-type="pmid">27832441</pub-id></element-citation></ref><ref id="B12-ijms-24-06424"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elson</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Sartor</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Tennyson</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Riddell</surname><given-names>R.H.</given-names></name></person-group><article-title>Experimental Models of Inflammatory Bowel Disease</article-title><source>Gastroenterology</source><year>1995</year><volume>109</volume><fpage>1344</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(95)90599-5</pub-id><pub-id pub-id-type="pmid">7557106</pub-id></element-citation></ref><ref id="B13-ijms-24-06424"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peterson</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Raoul</surname><given-names>J.M.</given-names></name></person-group><article-title>The Effect of Pentoxifylline and Its Metabolite-1 on Inflammation and Fibrosis in the TNBS Model of Colitis</article-title><source>Eur. J. Pharmacol.</source><year>2011</year><volume>662</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2011.04.030</pub-id><pub-id pub-id-type="pmid">21554874</pub-id></element-citation></ref><ref id="B14-ijms-24-06424"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiocchi</surname><given-names>C.</given-names></name></person-group><article-title>Inflammatory Bowel Disease: Etiology and Pathogenesis</article-title><source>Gastroenterology</source><year>1998</year><volume>115</volume><fpage>182</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(98)70381-6</pub-id><pub-id pub-id-type="pmid">9649475</pub-id></element-citation></ref><ref id="B15-ijms-24-06424"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neurath</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fuss</surname><given-names>I.</given-names></name><name name-style="western"><surname>Strober</surname><given-names>W.</given-names></name></person-group><article-title>TNBS-Colitis</article-title><source>Int. Rev. Immunol.</source><year>2000</year><volume>19</volume><fpage>51</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.3109/08830180009048389</pub-id><pub-id pub-id-type="pmid">10723677</pub-id></element-citation></ref><ref id="B16-ijms-24-06424"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma&#241;&#233;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lor&#233;n</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pedrosa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ojanguren</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dom&#232;nech</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gassull</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Cabr&#233;</surname><given-names>E.</given-names></name></person-group><article-title>Therapeutic Effect of Antisecretory Factor-Rich Egg Yolk on the Late Phases of 2,4,6-Trinitrobenzenesulphonic Acid Colitis in Mice</article-title><source>Br. J. Nutr.</source><year>2011</year><volume>106</volume><fpage>1522</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1017/S0007114511002042</pub-id><pub-id pub-id-type="pmid">21733301</pub-id></element-citation></ref><ref id="B17-ijms-24-06424"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Per&#353;e</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cerar</surname><given-names>A.</given-names></name></person-group><article-title>Dextran Sodium Sulphate Colitis Mouse Model: Traps and Tricks</article-title><source>J. Biomed. Biotechnol.</source><year>2012</year><volume>2012</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1155/2012/718617</pub-id><pub-id pub-id-type="pmid">22665990</pub-id><pub-id pub-id-type="pmcid">PMC3361365</pub-id></element-citation></ref><ref id="B18-ijms-24-06424"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poritz</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Garver</surname><given-names>K.I.</given-names></name><name name-style="western"><surname>Green</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ruggiero</surname><given-names>F.</given-names></name><name name-style="western"><surname>Koltun</surname><given-names>W.A.</given-names></name></person-group><article-title>Loss of the Tight Junction Protein ZO-1 in Dextran Sulfate Sodium Induced Colitis</article-title><source>J. Surg. Res.</source><year>2007</year><volume>140</volume><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.jss.2006.07.050</pub-id><pub-id pub-id-type="pmid">17418867</pub-id></element-citation></ref><ref id="B19-ijms-24-06424"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X.-Y.</given-names></name><name name-style="western"><surname>Son</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>J.-W.</given-names></name><name name-style="western"><surname>Joo</surname><given-names>M.-K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.-H.</given-names></name></person-group><article-title>Tight Junction Protein Expression-Inducing Probiotics Alleviate TNBS-Induced Cognitive Impairment with Colitis in Mice</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><elocation-id>2975</elocation-id><pub-id pub-id-type="doi">10.3390/nu14142975</pub-id><pub-id pub-id-type="pmid">35889931</pub-id><pub-id pub-id-type="pmcid">PMC9317072</pub-id></element-citation></ref><ref id="B20-ijms-24-06424"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Y.-T.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.-K.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>W.</given-names></name></person-group><article-title>Neutralization of IL-6 and TNF-&#945; Ameliorates Intestinal Permeability in DSS-Induced Colitis</article-title><source>Cytokine</source><year>2016</year><volume>83</volume><fpage>189</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2016.04.012</pub-id><pub-id pub-id-type="pmid">27155817</pub-id></element-citation></ref><ref id="B21-ijms-24-06424"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiesler</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fuss</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Strober</surname><given-names>W.</given-names></name></person-group><article-title>Experimental Models of Inflammatory Bowel Diseases</article-title><source>Cell. Mol. Gastroenterol. Hepatol.</source><year>2015</year><volume>1</volume><fpage>154</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2015.01.006</pub-id><pub-id pub-id-type="pmid">26000334</pub-id><pub-id pub-id-type="pmcid">PMC4435576</pub-id></element-citation></ref><ref id="B22-ijms-24-06424"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verd&#250;</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bercik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>S.M.</given-names></name></person-group><article-title>Modulatory Effects of Estrogen in Two Murine Models of Experimental Colitis</article-title><source>Am. J. Physiol. Liver Physiol.</source><year>2002</year><volume>283</volume><fpage>G27</fpage><lpage>G36</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00460.2001</pub-id><pub-id pub-id-type="pmid">12065288</pub-id></element-citation></ref><ref id="B23-ijms-24-06424"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#225;b&#237;&#269;kov&#225;</surname><given-names>J.</given-names></name><name name-style="western"><surname>T&#243;thov&#225;</surname><given-names>&#317;.</given-names></name><name name-style="western"><surname>Lengyelov&#225;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Barto&#328;ov&#225;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hodosy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gardl&#237;k</surname><given-names>R.</given-names></name><name name-style="western"><surname>Celec</surname><given-names>P.</given-names></name></person-group><article-title>Sex Differences in Experimentally Induced Colitis in Mice: A Role for Estrogens</article-title><source>Inflammation</source><year>2015</year><volume>38</volume><fpage>1996</fpage><lpage>2006</lpage><pub-id pub-id-type="doi">10.1007/s10753-015-0180-7</pub-id><pub-id pub-id-type="pmid">25962374</pub-id></element-citation></ref><ref id="B24-ijms-24-06424"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Connor</surname><given-names>M.-F.</given-names></name><name name-style="western"><surname>Motivala</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Valladares</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Olmstead</surname><given-names>R.</given-names></name><name name-style="western"><surname>Irwin</surname><given-names>M.R.</given-names></name></person-group><article-title>Sex Differences in Monocyte Expression of IL-6: Role of Autonomic Mechanisms</article-title><source>Am. J. Physiol. Integr. Comp. Physiol.</source><year>2007</year><volume>293</volume><fpage>R145</fpage><lpage>R151</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.00752.2006</pub-id><pub-id pub-id-type="pmid">17428894</pub-id></element-citation></ref><ref id="B25-ijms-24-06424"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagnerova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Babickova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liptak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vlkova</surname><given-names>B.</given-names></name><name name-style="western"><surname>Celec</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gardlik</surname><given-names>R.</given-names></name></person-group><article-title>Sex Differences in the Effect of Resveratrol on DSS-Induced Colitis in Mice</article-title><source>Gastroenterol. Res. Pract.</source><year>2017</year><volume>2017</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1155/2017/8051870</pub-id><pub-id pub-id-type="pmid">28465680</pub-id><pub-id pub-id-type="pmcid">PMC5390549</pub-id></element-citation></ref><ref id="B26-ijms-24-06424"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>AlSharari</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Bagdas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Akbarali</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Lichtman</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Raborn</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>F.I.</given-names></name><name name-style="western"><surname>McGee</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Damaj</surname><given-names>M.I.</given-names></name></person-group><article-title>Sex Differences and Drug Dose Influence the Role of the A7 Nicotinic Acetylcholine Receptor in the Mouse Dextran Sodium Sulfate-Induced Colitis Model</article-title><source>Nicotine Tob. Res.</source><year>2017</year><volume>19</volume><fpage>460</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1093/ntr/ntw245</pub-id><pub-id pub-id-type="pmid">27639096</pub-id><pub-id pub-id-type="pmcid">PMC6894014</pub-id></element-citation></ref><ref id="B27-ijms-24-06424"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hases</surname><given-names>L.</given-names></name><name name-style="western"><surname>Birgersson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Indukuri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C.</given-names></name></person-group><article-title>Colitis Induces Sex-Specific Intestinal Transcriptomic Responses in Mice</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>10408</elocation-id><pub-id pub-id-type="doi">10.3390/ijms231810408</pub-id><pub-id pub-id-type="pmid">36142324</pub-id><pub-id pub-id-type="pmcid">PMC9499483</pub-id></element-citation></ref><ref id="B28-ijms-24-06424"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Houser</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Caudle</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kannarkat</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>D.</given-names></name><name name-style="western"><surname>Joers</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Keshavarzian</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Experimental Colitis Promotes Sustained, Sex-Dependent, T-Cell-Associated Neuroinflammation and Parkinsonian Neuropathology</article-title><source>Acta Neuropathol. Commun.</source><year>2021</year><volume>9</volume><fpage>139</fpage><pub-id pub-id-type="doi">10.1186/s40478-021-01240-4</pub-id><pub-id pub-id-type="pmid">34412704</pub-id><pub-id pub-id-type="pmcid">PMC8375080</pub-id></element-citation></ref><ref id="B29-ijms-24-06424"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeeff</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Kunne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bouma</surname><given-names>G.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>te Velde</surname><given-names>A.A.</given-names></name></person-group><article-title>Actual Usage and Quality of Experimental Colitis Models in Preclinical Efficacy Testing</article-title><source>Inflamm. Bowel Dis.</source><year>2016</year><volume>22</volume><fpage>1296</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000000758</pub-id><pub-id pub-id-type="pmid">27104821</pub-id></element-citation></ref><ref id="B30-ijms-24-06424"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sies</surname><given-names>H.</given-names></name></person-group><article-title>Oxidative Stress: A Concept in Redox Biology and Medicine</article-title><source>Redox Biol.</source><year>2015</year><volume>4</volume><fpage>180</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2015.01.002</pub-id><pub-id pub-id-type="pmid">25588755</pub-id><pub-id pub-id-type="pmcid">PMC4309861</pub-id></element-citation></ref><ref id="B31-ijms-24-06424"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keshavarzian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Doria</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Sedghi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kanofsky</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>D.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>C.</given-names></name><name name-style="western"><surname>List</surname><given-names>T.</given-names></name><name name-style="western"><surname>Urban</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gaginella</surname><given-names>T.</given-names></name></person-group><article-title>Mitomycin C-Induced Colitis in Rats: A New Animal Model of Acute Colonic Inflammation Implicating Reactive Oxygen Species</article-title><source>J. Lab. Clin. Med.</source><year>1992</year><volume>120</volume><fpage>778</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">1431507</pub-id></element-citation></ref><ref id="B32-ijms-24-06424"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asghar</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Emani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>C.</given-names></name><name name-style="western"><surname>Helenius</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>Gr&#246;nroos</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Sareila</surname><given-names>O.</given-names></name><name name-style="western"><surname>Din</surname><given-names>M.U.</given-names></name><name name-style="western"><surname>Holmdahl</surname><given-names>R.</given-names></name><name name-style="western"><surname>H&#228;nninen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Toivola</surname><given-names>D.M.</given-names></name></person-group><article-title>In Vivo Imaging of Reactive Oxygen and Nitrogen Species in Murine Colitis</article-title><source>Inflamm. Bowel Dis.</source><year>2014</year><volume>20</volume><fpage>1435</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000000118</pub-id><pub-id pub-id-type="pmid">24983980</pub-id></element-citation></ref><ref id="B33-ijms-24-06424"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simmonds</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>T.R.J.</given-names></name><name name-style="western"><surname>Niall</surname><given-names>R.</given-names></name><name name-style="western"><surname>Van Someren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blake</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Rampton</surname><given-names>D.S.</given-names></name></person-group><article-title>Chemiluminescence Assay of Mucosal Reactive Oxygen Metabolites in Inflammatory Bowel Disease</article-title><source>Gastroenterology</source><year>1992</year><volume>103</volume><fpage>186</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(92)91112-H</pub-id><pub-id pub-id-type="pmid">1319369</pub-id></element-citation></ref><ref id="B34-ijms-24-06424"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keshavarzian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sedghi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kanofsky</surname><given-names>J.</given-names></name><name name-style="western"><surname>List</surname><given-names>T.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>C.</given-names></name><name name-style="western"><surname>Winship</surname><given-names>D.</given-names></name></person-group><article-title>Excessive Production of Reactive Oxygen Metabolites by Inflamed Colon: Analysis by Chemiluminescence Probe</article-title><source>Gastroenterology</source><year>1992</year><volume>103</volume><fpage>177</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(92)91111-G</pub-id><pub-id pub-id-type="pmid">1612325</pub-id></element-citation></ref><ref id="B35-ijms-24-06424"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhardwaj</surname><given-names>P.</given-names></name></person-group><article-title>Oxidative Stress and Antioxidants in Gastrointestinal Diseases</article-title><source>Trop. Gastroenterol.</source><year>2008</year><volume>29</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">19115604</pub-id></element-citation></ref><ref id="B36-ijms-24-06424"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vavassori</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mencarelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Renga</surname><given-names>B.</given-names></name><name name-style="western"><surname>Distrutti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fiorucci</surname><given-names>S.</given-names></name></person-group><article-title>The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity</article-title><source>J. Immunol.</source><year>2009</year><volume>183</volume><fpage>6251</fpage><lpage>6261</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0803978</pub-id><pub-id pub-id-type="pmid">19864602</pub-id></element-citation></ref><ref id="B37-ijms-24-06424"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Immunomodulatory Effects of Fentanyl and Morphine on DSS- and TNBS-Induced Colitis</article-title><source>Immunopharmacol. Immunotoxicol.</source><year>2022</year><volume>44</volume><fpage>1044</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1080/08923973.2022.2102993</pub-id><pub-id pub-id-type="pmid">35848944</pub-id></element-citation></ref><ref id="B38-ijms-24-06424"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>OH</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>CHO</surname><given-names>K.-A.</given-names></name><name name-style="western"><surname>KANG</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>KIM</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>WOO</surname><given-names>S.-Y.</given-names></name></person-group><article-title>Comparison of Experimental Mouse Models of Inflammatory Bowel Disease</article-title><source>Int. J. Mol. Med.</source><year>2014</year><volume>33</volume><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2013.1569</pub-id><pub-id pub-id-type="pmid">24285285</pub-id></element-citation></ref><ref id="B39-ijms-24-06424"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Du</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>MicroRNA-31 Reduces Inflammatory Signaling and Promotes Regeneration in Colon Epithelium, and Delivery of Mimics in Microspheres Reduces Colitis in Mice</article-title><source>Gastroenterology</source><year>2019</year><volume>156</volume><fpage>2281</fpage><lpage>2296.e6</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2019.02.023</pub-id><pub-id pub-id-type="pmid">30779922</pub-id></element-citation></ref><ref id="B40-ijms-24-06424"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Polydatin Alleviates DSS- and TNBS-Induced Colitis by Suppressing Th17 Cell Differentiation via Directly Inhibiting STAT3</article-title><source>Phytother. Res.</source><year>2022</year><volume>36</volume><fpage>3662</fpage><lpage>3671</lpage><pub-id pub-id-type="doi">10.1002/ptr.7533</pub-id><pub-id pub-id-type="pmid">35766233</pub-id></element-citation></ref><ref id="B41-ijms-24-06424"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Fbxw7 Increases CCL2/7 in CX3CR1hi Macrophages to Promote Intestinal Inflammation</article-title><source>J. Clin. Investig.</source><year>2019</year><volume>129</volume><fpage>3877</fpage><lpage>3893</lpage><pub-id pub-id-type="doi">10.1172/JCI123374</pub-id><pub-id pub-id-type="pmid">31246581</pub-id><pub-id pub-id-type="pmcid">PMC6715366</pub-id></element-citation></ref><ref id="B42-ijms-24-06424"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheibe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schmied</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vieth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Primbs</surname><given-names>T.</given-names></name><name name-style="western"><surname>Carl&#233;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Knieling</surname><given-names>F.</given-names></name><name name-style="western"><surname>Claussen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Klimowicz</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice With Chronic Intestinal Inflammation</article-title><source>Gastroenterology</source><year>2019</year><volume>156</volume><fpage>1082</fpage><lpage>1097.e11</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.11.029</pub-id><pub-id pub-id-type="pmid">30452921</pub-id></element-citation></ref><ref id="B43-ijms-24-06424"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taghipour</surname><given-names>N.</given-names></name><name name-style="western"><surname>Molaei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mosaffa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rostami-Nejad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Asadzadeh Aghdaei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Anissian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Azimzadeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zali</surname><given-names>M.R.</given-names></name></person-group><article-title>An Experimental Model of Colitis Induced by Dextran Sulfate Sodium from Acute Progresses to Chronicity in C57BL/6: Correlation between Conditions of Mice and the Environment</article-title><source>Gastroenterol. Hepatol. Bed Bench</source><year>2016</year><volume>9</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">26744614</pub-id><pub-id pub-id-type="pmcid">PMC4702041</pub-id></element-citation></ref><ref id="B44-ijms-24-06424"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemed-Shaked</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cowman</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ovadia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Amar</surname><given-names>K.-O.</given-names></name><name name-style="western"><surname>Eshkar-Sebban</surname><given-names>L.</given-names></name><name name-style="western"><surname>Melamed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lev</surname><given-names>L.B.</given-names></name><etal/></person-group><article-title>MTADV 5-MER Peptide Suppresses Chronic Inflammations as Well as Autoimmune Pathologies and Unveils a New Potential Target-Serum Amyloid A</article-title><source>J. Autoimmun.</source><year>2021</year><volume>124</volume><fpage>102713</fpage><pub-id pub-id-type="doi">10.1016/j.jaut.2021.102713</pub-id><pub-id pub-id-type="pmid">34390919</pub-id></element-citation></ref><ref id="B45-ijms-24-06424"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jena</surname><given-names>G.</given-names></name><name name-style="western"><surname>Trivedi</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Sandala</surname><given-names>B.</given-names></name></person-group><article-title>Oxidative Stress in Ulcerative Colitis: An Old Concept but a New Concern</article-title><source>Free. Radic. Res.</source><year>2012</year><volume>46</volume><fpage>1339</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.3109/10715762.2012.717692</pub-id><pub-id pub-id-type="pmid">22856328</pub-id></element-citation></ref><ref id="B46-ijms-24-06424"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alzoghaibi</surname><given-names>M.A.</given-names></name></person-group><article-title>Concepts of Oxidative Stress and Antioxidant Defense in Crohn&#8217;s Disease</article-title><source>World J. Gastroenterol.</source><year>2013</year><volume>19</volume><fpage>6540</fpage><pub-id pub-id-type="doi">10.3748/wjg.v19.i39.6540</pub-id><pub-id pub-id-type="pmid">24151379</pub-id><pub-id pub-id-type="pmcid">PMC3801366</pub-id></element-citation></ref><ref id="B47-ijms-24-06424"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antoniou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Margonis</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Angelou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pikouli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Argiri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Karavokyros</surname><given-names>I.</given-names></name><name name-style="western"><surname>Papalois</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pikoulis</surname><given-names>E.</given-names></name></person-group><article-title>The TNBS-Induced Colitis Animal Model: An Overview</article-title><source>Ann. Med. Surg.</source><year>2016</year><volume>11</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.amsu.2016.07.019</pub-id><pub-id pub-id-type="pmcid">PMC5021709</pub-id><pub-id pub-id-type="pmid">27656280</pub-id></element-citation></ref><ref id="B48-ijms-24-06424"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>S.</given-names></name><name name-style="western"><surname>Specian</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Grisham</surname><given-names>M.B.</given-names></name></person-group><article-title>A Comparative Analysis of Two Models of Colitis in Rats</article-title><source>Gastroenterology</source><year>1992</year><volume>102</volume><fpage>1524</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(92)91710-L</pub-id><pub-id pub-id-type="pmid">1314749</pub-id></element-citation></ref><ref id="B49-ijms-24-06424"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidal-Lletj&#243;s</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andriamihaja</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blais</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grauso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lepage</surname><given-names>P.</given-names></name><name name-style="western"><surname>Davila</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Gaudichon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leclerc</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blachier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>A.</given-names></name></person-group><article-title>Mucosal Healing Progression after Acute Colitis in Mice</article-title><source>World J. Gastroenterol.</source><year>2019</year><volume>25</volume><fpage>3572</fpage><lpage>3589</lpage><pub-id pub-id-type="doi">10.3748/wjg.v25.i27.3572</pub-id><pub-id pub-id-type="pmid">31367158</pub-id><pub-id pub-id-type="pmcid">PMC6658396</pub-id></element-citation></ref><ref id="B50-ijms-24-06424"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Q.W.</given-names></name><name name-style="western"><surname>Kashiwabara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>C.</given-names></name></person-group><article-title>Role of Transcription Factor NF-Kappa B/Rel in Induction of Nitric Oxide Synthase</article-title><source>J. Biol. Chem.</source><year>1994</year><volume>269</volume><fpage>4705</fpage><lpage>4708</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(17)37600-7</pub-id><pub-id pub-id-type="pmid">7508926</pub-id></element-citation></ref><ref id="B51-ijms-24-06424"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rafa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saoula</surname><given-names>H.</given-names></name><name name-style="western"><surname>Belkhelfa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Medjeber</surname><given-names>O.</given-names></name><name name-style="western"><surname>Soufli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Toumi</surname><given-names>R.</given-names></name><name name-style="western"><surname>de Launoit</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moral&#232;s</surname><given-names>O.</given-names></name><name name-style="western"><surname>Nakmouche</surname><given-names>M.</given-names></name><name name-style="western"><surname>Delhem</surname><given-names>N.</given-names></name><etal/></person-group><article-title>IL-23/IL-17A Axis Correlates with the Nitric Oxide Pathway in Inflammatory Bowel Disease: Immunomodulatory Effect of Retinoic Acid</article-title><source>J. Interferon Cytokine Res.</source><year>2013</year><volume>33</volume><fpage>355</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1089/jir.2012.0063</pub-id><pub-id pub-id-type="pmid">23472658</pub-id></element-citation></ref><ref id="B52-ijms-24-06424"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rafa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Amri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saoula</surname><given-names>H.</given-names></name><name name-style="western"><surname>Belkhelfa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Medjeber</surname><given-names>O.</given-names></name><name name-style="western"><surname>Boutaleb</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aftis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakmouche</surname><given-names>M.</given-names></name><name name-style="western"><surname>Touil-Boukoffa</surname><given-names>C.</given-names></name></person-group><article-title>Involvement of Interferon-&#947; in Bowel Disease Pathogenesis by Nitric Oxide Pathway: A Study in Algerian Patients</article-title><source>J. Interferon Cytokine Res.</source><year>2010</year><volume>30</volume><fpage>691</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1089/jir.2010.0012</pub-id><pub-id pub-id-type="pmid">20626296</pub-id></element-citation></ref><ref id="B53-ijms-24-06424"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lor&#233;n</surname><given-names>V.</given-names></name><name name-style="western"><surname>Garcia-Jaraquemada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naves</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Carmona</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma&#241;osa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aransay</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lavin</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cabr&#233;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Many&#233;</surname><given-names>J.</given-names></name><etal/></person-group><article-title>ANP32E, a Protein Involved in Steroid-Refractoriness in Ulcerative Colitis, Identified by a Systems Biology Approach</article-title><source>J. Crohns Colitis</source><year>2019</year><volume>13</volume><fpage>351</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjy171</pub-id><pub-id pub-id-type="pmid">30329026</pub-id></element-citation></ref><ref id="B54-ijms-24-06424"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huscher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Thiele</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gromnica-Ihle</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hein</surname><given-names>G.</given-names></name><name name-style="western"><surname>Demary</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dreher</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zink</surname><given-names>A.</given-names></name><name name-style="western"><surname>Buttgereit</surname><given-names>F.</given-names></name></person-group><article-title>Dose-Related Patterns of Glucocorticoid-Induced Side Effects</article-title><source>Ann. Rheum. Dis.</source><year>2009</year><volume>68</volume><fpage>1119</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1136/ard.2008.092163</pub-id><pub-id pub-id-type="pmid">18684744</pub-id></element-citation></ref><ref id="B55-ijms-24-06424"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fardet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nazareth</surname><given-names>I.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>I.</given-names></name></person-group><article-title>Long-Term Systemic Glucocorticoid Therapy and Weight Gain: A Population-Based Cohort Study</article-title><source>Rheumatology</source><year>2021</year><volume>60</volume><fpage>1502</fpage><lpage>1511</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keaa289</pub-id><pub-id pub-id-type="pmid">32864693</pub-id></element-citation></ref><ref id="B56-ijms-24-06424"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chrousos</surname><given-names>G.P.</given-names></name></person-group><article-title>Stress and Sex Versus Immunity and Inflammation</article-title><source>Sci. Signal.</source><year>2010</year><volume>3</volume><pub-id pub-id-type="doi">10.1126/scisignal.3143pe36</pub-id><pub-id pub-id-type="pmid">20940425</pub-id></element-citation></ref><ref id="B57-ijms-24-06424"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wine</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Hyams</surname><given-names>J.</given-names></name><name name-style="western"><surname>Otley</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Markowitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Crandall</surname><given-names>W.V.</given-names></name><name name-style="western"><surname>Leleiko</surname><given-names>N.</given-names></name><name name-style="western"><surname>Muise</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>D.</given-names></name></person-group><article-title>Interleukin-6 Is Associated with Steroid Resistance and Reflects Disease Activity in Severe Pediatric Ulcerative Colitis</article-title><source>J. Crohn&#8217;s Colitis</source><year>2013</year><volume>7</volume><fpage>916</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1016/j.crohns.2012.12.012</pub-id><pub-id pub-id-type="pmid">23339932</pub-id></element-citation></ref><ref id="B58-ijms-24-06424"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kriel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sayers</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zacharowski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Probert</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Tobias</surname><given-names>J.H.</given-names></name></person-group><article-title>IL-6 May Modulate the Skeletal Response to Glucocorticoids During Exacerbations of Inflammatory Bowel Disease</article-title><source>Calcif. Tissue Int.</source><year>2010</year><volume>86</volume><fpage>375</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1007/s00223-010-9345-4</pub-id><pub-id pub-id-type="pmid">20229252</pub-id></element-citation></ref><ref id="B59-ijms-24-06424"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabay</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kushner</surname><given-names>I.</given-names></name></person-group><article-title>Acute-Phase Proteins and Other Systemic Responses to Inflammation</article-title><source>N. Engl. J. Med.</source><year>1999</year><volume>340</volume><fpage>448</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1056/NEJM199902113400607</pub-id><pub-id pub-id-type="pmid">9971870</pub-id></element-citation></ref><ref id="B60-ijms-24-06424"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cushing</surname><given-names>K.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>P.D.R.</given-names></name></person-group><article-title>Management of Crohn Disease</article-title><source>JAMA</source><year>2021</year><volume>325</volume><fpage>69</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.18936</pub-id><pub-id pub-id-type="pmid">33399844</pub-id><pub-id pub-id-type="pmcid">PMC9183209</pub-id></element-citation></ref><ref id="B61-ijms-24-06424"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>I.</given-names></name><name name-style="western"><surname>Solas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mateus</surname><given-names>V.</given-names></name></person-group><article-title>Chronic Experimental Model of TNBS-Induced Colitis to Study Inflammatory Bowel Disease</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>4739</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23094739</pub-id><pub-id pub-id-type="pmid">35563130</pub-id><pub-id pub-id-type="pmcid">PMC9105049</pub-id></element-citation></ref><ref id="B62-ijms-24-06424"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindsay</surname><given-names>J.</given-names></name><name name-style="western"><surname>van Montfrans</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>F.</given-names></name><name name-style="western"><surname>van Deventer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Drillenburg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hodgson</surname><given-names>H.</given-names></name><name name-style="western"><surname>te Velde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pena</surname><given-names>M.S.R.</given-names></name></person-group><article-title>IL-10 Gene Therapy Prevents TNBS-Induced Colitis</article-title><source>Gene Ther.</source><year>2002</year><volume>9</volume><fpage>1715</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3301841</pub-id><pub-id pub-id-type="pmid">12457286</pub-id></element-citation></ref><ref id="B63-ijms-24-06424"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scaldaferri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vetrano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sans</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arena</surname><given-names>V.</given-names></name><name name-style="western"><surname>Straface</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stigliano</surname><given-names>E.</given-names></name><name name-style="western"><surname>Repici</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sturm</surname><given-names>A.</given-names></name><name name-style="western"><surname>Malesci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Panes</surname><given-names>J.</given-names></name><etal/></person-group><article-title>VEGF-A Links Angiogenesis and Inflammation in Inflammatory Bowel Disease Pathogenesis</article-title><source>Gastroenterology</source><year>2009</year><volume>136</volume><fpage>585</fpage><lpage>595.e5</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.09.064</pub-id><pub-id pub-id-type="pmid">19013462</pub-id></element-citation></ref><ref id="B64-ijms-24-06424"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giatromanolaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sivridis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maltezos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Papazoglou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Simopoulos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gatter</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Koukourakis</surname><given-names>M.I.</given-names></name></person-group><article-title>Hypoxia Inducible Factor 1 and 2 Overexpression in Inflammatory Bowel Disease</article-title><source>J. Clin. Pathol.</source><year>2003</year><volume>56</volume><fpage>209</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1136/jcp.56.3.209</pub-id><pub-id pub-id-type="pmid">12610101</pub-id><pub-id pub-id-type="pmcid">PMC1769899</pub-id></element-citation></ref><ref id="B65-ijms-24-06424"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kruschewski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Foitzik</surname><given-names>T.</given-names></name><name name-style="western"><surname>Perez-Cant&#243;</surname><given-names>A.</given-names></name><name name-style="western"><surname>H&#252;botter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Buhr</surname><given-names>H.J.</given-names></name></person-group><article-title>Changes of Colonic Mucosal Microcirculation and Histology in Two Colitis Models: An Experimental Study Using Intravital Microscopy and a New Histological Scoring System</article-title><source>Dig. Dis. Sci.</source><year>2001</year><volume>46</volume><fpage>2336</fpage><lpage>2343</lpage><pub-id pub-id-type="doi">10.1023/A:1012334727509</pub-id><pub-id pub-id-type="pmid">11713932</pub-id></element-citation></ref><ref id="B66-ijms-24-06424"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karhausen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Furuta</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Tomaszewski</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Colgan</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Haase</surname><given-names>V.H.</given-names></name></person-group><article-title>Epithelial Hypoxia-Inducible Factor-1 Is Protective in Murine Experimental Colitis</article-title><source>J. Clin. Investig.</source><year>2004</year><volume>114</volume><fpage>1098</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1172/JCI200421086</pub-id><pub-id pub-id-type="pmid">15489957</pub-id><pub-id pub-id-type="pmcid">PMC522241</pub-id></element-citation></ref><ref id="B67-ijms-24-06424"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buckley</surname><given-names>A.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>J.R.</given-names></name></person-group><article-title>Cell Biology of Tight Junction Barrier Regulation and Mucosal Disease</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2018</year><volume>10</volume><elocation-id>a029314</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a029314</pub-id><pub-id pub-id-type="pmid">28507021</pub-id><pub-id pub-id-type="pmcid">PMC5749156</pub-id></element-citation></ref><ref id="B68-ijms-24-06424"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zolotarevsky</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>G.</given-names></name><name name-style="western"><surname>Koutsouris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mrsny</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>J.R.</given-names></name></person-group><article-title>A Membrane-Permeant Peptide That Inhibits MLC Kinase Restores Barrier Function in In Vitro Models of Intestinal Disease</article-title><source>Gastroenterology</source><year>2002</year><volume>123</volume><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1053/gast.2002.34235</pub-id><pub-id pub-id-type="pmid">12105845</pub-id></element-citation></ref><ref id="B69-ijms-24-06424"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerber</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Padberg</surname><given-names>C.</given-names></name><name name-style="western"><surname>Koll</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schuetzhold</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fandrey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Winning</surname><given-names>S.</given-names></name></person-group><article-title>The Importance of Hypoxia-Inducible Factors (HIF-1 and HIF-2) for the Pathophysiology of Inflammatory Bowel Disease</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>8551</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21228551</pub-id><pub-id pub-id-type="pmid">33202783</pub-id><pub-id pub-id-type="pmcid">PMC7697655</pub-id></element-citation></ref><ref id="B70-ijms-24-06424"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.-E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Im</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name><etal/></person-group><article-title>Hypoxia-Inducible Factor-1 (HIF-1) Activation in Myeloid Cells Accelerates DSS-Induced Colitis Progression in Mice</article-title><source>Dis. Model. Mech.</source><year>2018</year><volume>11</volume><fpage>dmm033241</fpage><pub-id pub-id-type="doi">10.1242/dmm.033241</pub-id><pub-id pub-id-type="pmid">29967068</pub-id><pub-id pub-id-type="pmcid">PMC6078398</pub-id></element-citation></ref><ref id="B71-ijms-24-06424"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>MacNaughton</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>P.L.</given-names></name></person-group><article-title>Inhibition of Leukotriene Synthesis Markedly Accelerates Healing in a Rat Model of Inflammatory Bowel Disease</article-title><source>Gastroenterology</source><year>1989</year><volume>96</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(89)90760-9</pub-id><pub-id pub-id-type="pmid">2535830</pub-id></element-citation></ref><ref id="B72-ijms-24-06424"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Livak</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Schmittgen</surname><given-names>T.D.</given-names></name></person-group><article-title>Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2&#8722;&#916;&#916;CT Method</article-title><source>Methods</source><year>2001</year><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-24-06424-f001" orientation="portrait"><label>Figure 1</label><caption><p>Bioluminescence evaluations in the follow-up of the TNBS model. (<bold>A</bold>) BLI is represented as median FC &#177; SE in the follow-up, represents therapeutic and preventive approaches, and is stratified by sex. Colors and dots denote treatment groups. Tables showing the statistical test (UMW) between sexes at each time point are given. (<bold>B</bold>) Graphical representation of bioluminescent images of each trial and treatment at each time point. Blue color represents the minimum pixel level, and red color the maximum pixel density. Asterisks indicate differences between treatments and vehicle administration, whereas pads mark differences between dexamethasone and MTADV treatments at each time point (Kruskal&#8211;Wallis with posthoc Dunn&#8217;s test). Significance levels: */<sup>#</sup> 0.01 &#8804; <italic toggle="yes">p</italic>-value &#8804; 0.05. BLI, bioluminescence intensity; dex, dexamethasone; F, female; FC, fold-change; M, male; MTADV, 5-MER peptide methionine-threonine-alanine-aspartic acid-valine; SE, standard error; TNBS, trinitrobenzenesulfonic acid; UMW, U Mann&#8211;Whitney test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-06424-g001.jpg"/></fig><fig position="float" id="ijms-24-06424-f002" orientation="portrait"><label>Figure 2</label><caption><p>Bioluminescence evaluations in the follow-up of the DSS model. (<bold>A</bold>) BLI is represented as median FC &#177; SE in the follow-up, represents therapeutic and preventive approaches, and is stratified by sex. Colors and dots denote treatment groups. Tables showing the statistical test (UMW) between sexes at each time point are given. (<bold>B</bold>) Graphical representation of bioluminescent images of each trial and treatment at each time point. Blue color represents the minimum pixel level, and red color the maximum pixel density. Asterisks indicate differences between treatments and vehicle administration, whereas pads mark differences between dexamethasone and MTADV treatments at each time point (Kruskal&#8211;Wallis with posthoc Dunn&#8217;s test). Significance levels: */<sup>#</sup> 0.01 &#8804; <italic toggle="yes">p</italic>-value &#8804; 0.05. BLI, bioluminescence intensity; dex, dexamethasone; DSS, dextran sulfate sodium; F, female; FC, fold-change; M, male; MTADV, 5-MER peptide methionine-threonine-alanine-aspartic acid-valine; SE, standard error; UMW, U Mann&#8211;Whitney test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-06424-g002.jpg"/></fig><fig position="float" id="ijms-24-06424-f003" orientation="portrait"><label>Figure 3</label><caption><p>Macroscopic evaluations in the follow-up of the TNBS model. (<bold>A</bold>) Body weight is represented as median FC &#177; SE in the follow-up, represents therapeutic and preventive approaches, and is stratified by sex. Colors and dots denote treatment groups. Tables showing the statistical test (UMW) between sexes at each time point are given. (<bold>B</bold>) Morphometric data are represented for both therapeutic and preventive trials. Data are represented as bar plots (median &#177; SD). Each variable and metric are given on the Y-axis, while colors indicate the treatment group. Asterisks indicate differences between treatments and vehicle administration, whereas pads mark differences between dexamethasone and MTADV treatments at each time point (Kruskal&#8211;Wallis with posthoc Dunn&#8217;s test). Significance levels: */<sup>#</sup> 0.01 &#8804; <italic toggle="yes">p</italic>-value &#8804; 0.05. BLI, bioluminescence intensity; dex, dexamethasone; F, female; FC, fold-change; M, male; MTADV, 5-MER peptide methionine-threonine-alanine-aspartic acid-valine; SD, standard deviation; SE, standard error; TNBS, trinitrobenzenesulfonic acid; UMW, U Mann&#8211;Whitney test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-06424-g003.jpg"/></fig><fig position="float" id="ijms-24-06424-f004" orientation="portrait"><label>Figure 4</label><caption><p>Macroscopic evaluations in the follow-up of the DSS model. (<bold>A</bold>) Body weight is represented as median FC &#177; SE in the follow-up, represents therapeutic and preventive approaches, and is stratified by sex. Colors and dots denote treatment groups. Tables showing the statistical test (UMW) between sexes at each time point are given. (<bold>B</bold>) Morphometric data are represented for both therapeutic and preventive trials. Data are represented as bar plots (median &#177; SD). Each variable and metric are given on the Y-axis, while colors indicate the treatment group. Asterisks indicate differences between treatments and vehicle administration, whereas pads mark differences between dexamethasone and MTADV treatments at each time point (Kruskal&#8211;Wallis with posthoc Dunn&#8217;s test). Significance levels: */<sup>#</sup> 0.01 &#8804; <italic toggle="yes">p</italic>-value &#8804; 0.05. BLI, bioluminescence intensity; dex, dexamethasone; DSS, dextran sulfate sodium; F, female; FC, fold-change; M, male; MTADV, 5-MER peptide methionine-threonine-alanine-aspartic acid-valine; SD, standard deviarion; SE, standard error; UMW, U Mann&#8211;Whitney test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-06424-g004.jpg"/></fig><fig position="float" id="ijms-24-06424-f005" orientation="portrait"><label>Figure 5</label><caption><p>mRNA expression of inflammatory markers in each treatment group in the affected mucosa. qRT-PCR quantified mRNA expression as FC of inflammatory markers for both therapeutic and preventive trials from the TNBS ((<bold>A</bold>) and (<bold>B</bold>), respectively)) and DSS models ((<bold>C</bold>) and (<bold>D</bold>), respectively). Data are represented as points summarized in boxplots, indicating IQR, and bars, indicating maximum and minimum. The median point is depicted as a bar inside the box. Treatment groups are differentiated using colors. Asterisks mark significance between the groups indicated by lines (Kruskall&#8211;Wallis test with a posthoc Dunn&#8217;s test). Significance levels are: * <italic toggle="yes">p</italic>-value &#8804; 0.05; ** <italic toggle="yes">p</italic>-value &#8804; 0.01; *** <italic toggle="yes">p</italic>-value &#8804; 0.001. Dex, dexamethasone; DSS, dextran sulphate sodium; FC, fold-change; IQR, interquartile range; MTADV, 5-MER peptide methionine-threonine-alanine-aspartic acid-valine; TNBS, trinitrobenzenesulfonic acid.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-06424-g005.jpg"/></fig><fig position="float" id="ijms-24-06424-f006" orientation="portrait"><label>Figure 6</label><caption><p>Representation of the inflammatory process induced in the colonic mucosa of both TNBS and DSS models. TNBS changes the conformation of antigens in the colonic mucosa, making it alien to the host immune system and thereby initiating transmural colitis. Dendritic cells recognizing these antigens drive the inflammatory process to Th1 and Th17 phenotypes which are also characterized by infiltration of the lamina propria with CD4+ T cells, neutrophils, and macrophages by the systemic production of APPs. It also drives T-cell differentiation to the T-reg phenotype but shows a more pronounced increment of pro-inflammatory cells. The hypoxic environment and macrophages activated by Th1 cells promote angiogenesis and mucosal immune barrier reparation (tight junctions) [<xref rid="B21-ijms-24-06424" ref-type="bibr">21</xref>]. DSS causes disruption of the intestinal epithelial barrier and, thereby, the entry of luminal bacteria or bacterial antigens into the mucosa. Neutrophil and dendritic cell detection of PAMPs by TLR, among others, provoke the start of inflammation, characterized by a Th1 phenotype in acute models and a mix of both Th1 and Th2 in chronic colitis. Altogether, this increases the production of APPs and decreases angiogenesis and mucins and tight junction protein expression with an imbalance between pro-inflammatory and anti-inflammatory cytokines [<xref rid="B21-ijms-24-06424" ref-type="bibr">21</xref>]. Created with BioRender.com. APP, acute phase protein; PAMP, pathogen-associated molecular pattern; T helper cells; TLR, toll-like receptor; TNBS, trinitrobenzenesulfonic acid, T-reg, T regulatory cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-06424-g006.jpg"/></fig><fig position="float" id="ijms-24-06424-f007" orientation="portrait"><label>Figure 7</label><caption><p>Graphical representation of the experimental design of the four chemically induced colitis approaches. Experimental design throughout time for the preventive (<bold>A</bold>) and therapeutic (<bold>B</bold>) approaches for TNBS and the preventive (<bold>C</bold>) and therapeutic (<bold>D</bold>) trials in DSS mice. Time is represented as days. Negative days are prior to colitis inducer administration. Colitis inducer administration and in vivo imaging are indicated as arrows or brackets. Drug delivery is marked as syringes. End-point refers to the last day of the trial.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-06424-g007.jpg"/></fig><table-wrap position="float" id="ijms-24-06424-t001" orientation="portrait"><object-id pub-id-type="pii">ijms-24-06424-t001_Table 1</object-id><label>Table 1</label><caption><p>BLI raw data correlation to mRNA and protein levels from inflammatory and oxidative markers of the animals stratified by colitis model, experimental trial, and sex.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="4" align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin">
</th><th colspan="9" align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1">Intestinal mRNA</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1">Plasmatic APP</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Il10</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Tgfb1</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Il6</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Vegfa</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Tjp1</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Nos2</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Tnfa</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Hif1a</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Il1b1</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CRP</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SAA</th></tr></thead><tbody><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Both</bold>
<break/>
<bold>sexes</bold>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>TNBS</bold>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Ther</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF7585" rowspan="1" colspan="1">
<bold>0.02</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.63</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.04</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF7585" rowspan="1" colspan="1">
<bold>&#8722;0.42</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Prev</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.78</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.61</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF7585" rowspan="1" colspan="1">
<bold>0.03</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.32</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.11</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF7585" rowspan="1" colspan="1">
<bold>&#8722;0.42</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.26</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>DSS</bold>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Ther</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.09</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF7585" rowspan="1" colspan="1">
<bold>0.01</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.04</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.01</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.32</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF7585" rowspan="1" colspan="1">
<bold>&#8722;0.46</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.40</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.64</bold>
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Prev</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.35</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FFC7CE" rowspan="1" colspan="1">
<bold>0.05</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.69</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.39</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.19</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FFC7CE" rowspan="1" colspan="1">
<bold>&#8722;0.39</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.23</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>F</bold>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>TNBS</bold>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Ther</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.84</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.01</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.01</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.91</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.02</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.52</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.22</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.61</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.64</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.60</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Prev</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.64</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.17</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>DSS</bold>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Ther</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.68</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.22</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Prev</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.23</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.04</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.44</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.38</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.61</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.30</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>M</bold>
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>TNBS</bold>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Ther</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.79</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Prev</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.88</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.56</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.29</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>DSS</bold>
</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Ther</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF334B" rowspan="1" colspan="1">
<bold>0.00</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.88</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF334B" rowspan="1" colspan="1">
<bold>0.03</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF7585" rowspan="1" colspan="1">
<bold>0.05</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.92</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.40</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF334B" rowspan="1" colspan="1">
<bold>&#8722;0.81</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF334B" rowspan="1" colspan="1">
<bold>&#8722;0.60</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF7585" rowspan="1" colspan="1">
<bold>&#8722;0.57</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.09</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Prev</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.19</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF7585" rowspan="1" colspan="1">
<bold>0.04</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.36</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF7585" rowspan="1" colspan="1">
<bold>&#8722;0.54</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.37</td></tr></tbody></table><table-wrap-foot><fn><p>Spearman correlation analyses. Red and blue colors indicate significant (<italic toggle="yes">p</italic> &#8804; 0.05) negative and positive correlations. APP, acute phase proteins, BLI, Bioluminescence intensity; CRP, C-reactive protein; DSS, dextran sulfate sodium; F, female; M, male; <italic toggle="yes">p</italic>, <italic toggle="yes">p</italic>-value; Prev, Preventive; R, Rho; SAA, serum amyloid antigen; Ther, Therapeutic; TNBS, trinitrobenzenesulfonic acid.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-24-06424-t002" orientation="portrait"><object-id pub-id-type="pii">ijms-24-06424-t002_Table 2</object-id><label>Table 2</label><caption><p>Correlation between inflammatory and oxidative stress mRNA expression in the TNBS model in both therapeutic and preventive approaches.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Hif1a</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Il10</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Il6</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Nos2</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Tgfb1</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Tnfa</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Vegfa</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Tjp1</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Il1b1</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Hif1a</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.43</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.09</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.58</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.59</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.52</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Ther</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Il10</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.49</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.61</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.23</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.66</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.09</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.82</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Il6</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.70</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.28</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.29</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.61</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.50</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.52</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.33</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.52</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Nos2</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.41</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.55</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.57</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.15</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.47</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Tgfb1</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.75</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.23</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.76</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.32</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.40</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.28</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#BCCCEA" rowspan="1" colspan="1">
<bold>0.35</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#BCCCEA" rowspan="1" colspan="1">
<bold>0.39</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Tnfa</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.64</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.38</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.69</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.61</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.62</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.26</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.76</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Vegfa</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.75</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.23</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.87</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.71</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.61</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.48</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.28</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Tjp1</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.40</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.24</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Il1b1</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.61</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.90</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.46</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.72</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.66</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.79</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.05</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="9" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Preventive</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>Spearman linear regression analyses. Red and blue colors indicate significant (<italic toggle="yes">p</italic> &#8804; 0.05) negative and positive correlations, respectively. Grey diagonal separates therapeutic (top) from preventive (bottom) correlations. Prev, Preventive; Ther, Therapeutic; TNBS, trinitrobenzenesulfonic acid.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-24-06424-t003" orientation="portrait"><object-id pub-id-type="pii">ijms-24-06424-t003_Table 3</object-id><label>Table 3</label><caption><p>Correlation between inflammatory and oxidative stress mRNA expression in the DSS model in both therapeutic and preventive approaches.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Hif1a</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Il10</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Il6</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Nos2</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Tgfb1</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Tnfa</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Vegfa</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Tjp1</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Il1b1</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Hif1a</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.46</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.44</bold>
</td><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Ther</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Il10</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.13</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.19</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.5</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.23</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.43</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Il6</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.74</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.23</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.4</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.03</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#BCCCEA" rowspan="1" colspan="1">
<bold>0.38</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.19</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.91</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Nos2</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.13</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.28</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.82</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF334B" rowspan="1" colspan="1">
<bold>&#8722;0.68</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF334B" rowspan="1" colspan="1">
<bold>&#8722;0.73</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#BCCCEA" rowspan="1" colspan="1">
<bold>0.39</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Tgfb1</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.73</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.21</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.76</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.16</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.59</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.52</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.09</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Tnfa</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.49</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.16</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.44</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.44</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#BCCCEA" rowspan="1" colspan="1">
<bold>0.39</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF7585" rowspan="1" colspan="1">
<bold>&#8722;0.43</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF7585" rowspan="1" colspan="1">
<bold>&#8722;0.43</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.36</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Vegfa</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.24</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.58</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.82</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Tjp1</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#FF7585" rowspan="1" colspan="1">
<bold>&#8722;0.58</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.16</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.13</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">Il1b1</italic>
</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.64</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.77</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#5D84CB" rowspan="1" colspan="1">
<bold>0.68</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#8EA9DB" rowspan="1" colspan="1">
<bold>0.57</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.10</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="9" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Prev</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>Spearman linear regression analyses. Red and blue colors indicate significant (<italic toggle="yes">p</italic> &#8804; 0.05) negative and positive correlations, respectively. Grey diagonal separates therapeutic (top) from preventive (bottom) correlations. DSS, dextran sulfate sodium; Prev, Preventive; Ther, Therapeutic.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-24-06424-t004" orientation="portrait"><object-id pub-id-type="pii">ijms-24-06424-t004_Table 4</object-id><label>Table 4</label><caption><p>Proposed remarkable mRNA mucosal and plasmatic APPs inflammatory and reparation markers with a moderate-high correlation with ROS detection using bioluminescence stratified by model, approach, and sex.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approach</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Both Sexes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">F</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">M</italic>
</th></tr></thead><tbody><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>TNBS-colitis</bold>
</td><td rowspan="4" align="center" valign="middle" colspan="1">Therapeutic</td><td rowspan="4" align="center" valign="middle" colspan="1">
<italic toggle="yes">Tjp1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tnfa</italic>
</td><td rowspan="2" align="center" valign="middle" colspan="1">
<italic toggle="yes">Tgfb1<sup>t</sup></italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Il6</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Il1b1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Il6<sup>t</sup></italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tjp1<sup>t</sup> Il10/Il1b1 Tgfb1/Il1b1 Il10/Il6<sup>t</sup></italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Il1b1<sup>t</sup> Il10/Il6<sup>t</sup></italic>
</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Preventive</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CRP</td><td align="center" valign="middle" rowspan="1" colspan="1">CRP<sup>t</sup></td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<italic toggle="yes">Nos2<sup>t</sup></italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Il10/Il6<sup>t</sup></italic>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Il10/Il1b1<sup>t</sup></italic>
</td></tr><tr><td rowspan="11" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>DSS-colitis</bold>
</td><td rowspan="8" align="center" valign="middle" colspan="1">Therapeutic</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tgfb1</italic>
</td><td rowspan="4" align="center" valign="middle" colspan="1">
<italic toggle="yes">Tgfb1<sup>t</sup></italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tgfb1</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Il6</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Il6</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">SAA</italic>
</td><td rowspan="2" align="center" valign="middle" colspan="1">
<italic toggle="yes">Vegfa</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Il10/Il6</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tgfb1/Il6</italic>
</td><td rowspan="4" align="center" valign="middle" colspan="1">
<italic toggle="yes">Hif1a<sup>t</sup></italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tjp1</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tgfb1/Tnfa</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Il10/Tnfa</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Il10/Il1b1</italic>
</td><td rowspan="2" align="center" valign="middle" colspan="1">
<italic toggle="yes">Tgfb1/Tnfa</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tgfb1/Il1b1</italic>
</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Preventive</td><td rowspan="2" align="center" valign="middle" colspan="1">
<italic toggle="yes">Il6</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tjp1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Hif1a</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tnfa<sup>t</sup></italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Il6<sup>t</sup></italic>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Tgfb1/Il6</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Tgfb1/Il6<sup>t</sup></italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Tgfb1/Il6</italic>
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>t</sup> correlation was moderate but tendential. APP, Acute phase protein; CRP, C-reactive protein; DSS, dextran sulfate sodium; SAA, Serum amyloid antigen; TNBS, trinitrobenzenesulfonic acid.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>